

Author Index to CGC Volumes 79-85

- A**
 Abazis D, 80:68, 85:75
 Abbondandolo A, 79:133
 Abdelhay E, 84:32
 Abe A, 83:37
 Abe K, 80:155
 Abe T, 79:89, 81:20
 Abeliovich D, 81:115
 Acin P, 81:185
 Adachi K, 83:37
 Addis P, 80:80
 Adorno G, 79:82
 Adrone E, 79:25
 Agamanolis DP, 81:125
 Aguiar RCT, 84:105
 Ahearn J, 80:150
 Ahmann GJ, 83:61
 Akao Y, 81:186
 Alder H, 83:65
 Al-Jehani RMA, 85:26
 Allikmets R, 81:144
 Altungoz O, 79:104, 79:136
 Alwasia J, 85:61, 85:155
 Amadori S, 84:15
 Amarglio N, 83:140, 84:56
 Amiel A, 79:153, 83:115, 85:118
 Anand A, 83:178
 Andersson B, 82:35
 Andrén-Sandberg A, 82:146
 Andreeff M, 82:23
 Ankathil R, 83:71
 Ansari MR, 85:20
 Atillón-Klössmann F, 79:49
 Antonio JR, 85:16, 85:88
 Aoki K, 84:69
 Aozasa M, 79:89
 Arima T, 85:5
 Ariyama T, 81:20
 Armitage JO, 80:124
 Armstrong RF, 84:46
 Arnoulet C, 85:82
 Artan S, 79:86
 Arvelo F, 80:47
 Asahi Y, 82:54, 82:88
 Asko-Seljavaara S, 85:91
 Aspberg F, 79:119
 Atkin NB, 79:111, 84:90, 85:129
 Attias R, 84:1, 84:9
 Augustus M, 84:51

B
 Babinska M, 85:61
 Badia-Garrabou L, 83:82
 Baffa R, 83:65
 Bajer J, 79:82, 80:66
 Baker MC, 79:111, 84:90, 85:129
 Bakshi SR, 83:178
 Balar DB, 83:176
 Ballin A, 83:90
 Balsamo R, 82:116
 Barbanti-Brodano G, 80:167
 Barbara L, 79:123
 Barcia-Salorio JK, 85:113
 Bardenheuer W, 81:1
 Bardi A, 82:116
 Bardi G, 80:103, 80:110, 80:118, 82:82
 Barlogie B, 82:41
 Barrios C, 81:173
 Bartnitzke S, 80:33, 84:82
 Başaran N, 79:86
 Baserga M, 79:123
 Bast M, 80:124
 Bauer HCF, 79:119
 Beauchamp R, 84:24
 Becher R, 80:40
 Beitler B, 84:105
 Bello MJ, 83:160
 Bellomo MJ, 81:158
 Ben-Bassat I, 83:14, 85:1
 Bendit I, 84:105
 Bendix-Hansen K, 79:79
 Bengoechea E, 80:160, 83:119
 Benjes SM, 79:32
 Ben-Neriah S, 81:115
 Ben-Yehuda D, 81:115
 Bépier G, 84:39
 Berean K, 80:165
 Berger R, 79:130, 79:186
 Bergerheim USR, 81:144
 Beris Ph, 81:158
 Berkowicz M, 83:140
 Berman S, 83:140, 85:1
 Bernheim A, 80:47, 81:17
 Bernués M, 84:123
 Bhasker R, 80:115
 Bigoni R, 82:116
 Biniaminov M, 83:140
 Birch JM, 80:17
 Birdsall SH, 81:166, 83:111
 Black AJM, 81:166
 Blair V, 80:17
 Blomqvist C, 85:91
 Bohlander SK, 83:46
 Bolte KM, 80:33
 Bonassi S, 79:133
 Bonfatti A, 80:167
 Bonk U, 80:33
 Bono AV, 83:28
 Bonomi R, 79:186
 Boogaerts MA, 82:103
 Bornfield N, 80:40
 Borowska-Lehman J, 85:61
 Bosoni D, 79:123
 Botte KM, 80:33
 Bouabdallah R, 85:82
 Bourantas K, 84:91
 Bowyer S, 79:115
 Braun S, 84:85
 Brito-Babapulle V, 83:18
 Brock P, 80:121
 Brodsky I, 81:24
 Brok-Simoni F, 83:140, 84:56, 85:1
 Brooks JSJ, 79:104
 Brothman A, 84:113
 Brothman AR, 81:118, 85:143
 Brown N, 80:107
 Brozek I, 83:75
 Brun A, 80:83
 Brunel V, 85:82
 Brutel de la Rivière G, 79:164
 Büell U, 79:144
 Bullerdiek J, 79:1, 80:33, 84:82, 85:105
 Butler MG, 85:1
 Buys CHCM, 81:1
 Bydlowski S, 84:105

C
 Caballín MR, 80:78, 84:123
 Cabanillas F, 82:23
 Cabezo E, 80:158
 Cadiou M, 83:165
 Cahn TK, 82:76
 Calabrese G, 85:124
 Calasanz MJ, 80:160
 Calasanz Abinzano MJ, 83:119
 Camurri L, 79:133
 Cantonetti M, 84:15
 Cao Y, 79:149
 Capra E, 82:50, 84:89
 Carli MC, 82:116
 Carroll PR, 80:168
 Carter N, 80:87
 Caruso V, 83:28
 Casadevall G, 84:123
 Casalone R, 83:28
 Casati A, 79:41
 Caselitz J, 80:33, 84:82
 Cassiman J-J, 82:80, 83:25
 Castedo S, 82:140
 Casteels-Van Daele M, 80:121
 Castoldi G, 82:116, 83:65
 Castresana JS, 81:173
 Catovsky D, 83:136
 Catovsky P, 83:18
 Cavalli LR, 81:66
 Cavalli JJ, 81:66
 Cedrone E, 83:105
 Cerdá-Nicolás M, 85:113
 Chaganti RSK, 80:9, 81:139, 82:62
 Chamone D, 84:105
 Chan AM-L, 83:87
 Chan D, 85:159
 Chan JKC, 81:28, 82:73
 Chang LC, 81:76
 Chatel M, 84:1, 84:9
 Chen P, 82:106
 Chen S-J, 81:76
 Chen TR, 81:103
 Chen Y-C, 84:60
 Chen Z, 79:149, 81:76, 84:116
 Ching LM, 81:76
 Ching Cheng N, 82:151
 Chu Y, 85:89
 Chuang S-M, 84:60
 Chung J, 85:89
 Chyubachi A, 81:56
 Cigudosa J, 82:87
 Cigudosa JC, 80:160, 83:119
 Clausen N, 79:79, 84:19
 Cobos E, 80:135
 Cohen D, 81:1
 Cohen K, 82:30
 Coignet L, 85:82
 Coll MD, 80:78
 Collins P, 84:56
 Colla BM, 79:70
 Colombani P, 82:30
 Cometa G, 79:123
 Cooley LD, 80:138
 Cork A, 82:35
 Correa H, 80:20, 80:75, 81:94
 Corson JM, 79:139, 84:76
 Costello R, 85:82
 Cowell JK, 81:151
 Cox-Francis MC, 79:82, 80:66, 84:15
 Craver RD, 80:20, 80:75, 81:94
 Cremerius U, 79:144
 Crescenzi B, 79:182
 Creutzig U, 80:23
 Criado B, 82:140
 Creil A, 82:80
 Crilley P, 81:24
 Croce CM, 81:24, 83:65
 Crossen PE, 79:70
 Cuneo A, 82:116, 83:65
 Cymbalista-Ajchembaum F, 83:165

D
 Dadoune J-P, 83:165
 Daeschner C, 82:90
 Dahia PLM, 84:105
 Dahir GA, 85:51
 Dahlenfors R, 79:188
 Dal Cin P, 79:189, 80:121, 83:174
 Dal Prá L, 79:133
 Dam A, 79:164, 82:57
 Darlfer M, 79:97
 Dave BJ, 83:172
 David L, 82:140
 Dawski RL, 83:127
 Dawiskiba S, 82:146
 Dean M, 81:144
 Debic-Rychter M, 85:61, 85:155

- Debusscher C, 85:138
 de Campos JM, 83:160
 De Ferrari M, 79:133
 Degraasi F, 79:133
 De Groote B, 80:121
 de Jong B, 79:164, 82:161,
 84:95, 85:133, 85:152
 Del Maestro, 84:46
 Del Poeta G, 80:66
 Della-Rosa VA, 79:36
 Delmer A, 83:165
 Del Vecchio E, 79:123
 Demuyndt H, 82:103
 Denny C, 79:25
 de Oliveira Pozzetti EM, 85:16,
 85:88
 Deprez C, 85:138
 De Roy G, 85:138
 Derré J, 79:130
 Dervenoulas J, 80:162
 De Valck C, 85:138
 Dewald GW, 83:61
 De Wever I, 79:189, 83:17
 Dhillon VS, 80:115
 Di Bartolomeo P, 85:124
 Dictor M, 79:157
 Dijkhuizen T, 79:164, 82:161,
 84:95, 85:152
 DiPaolo JA, 80:100, 82:1
 Dobin SM, 83:56
 Dolfin AC, 84:27
 Dong S, 81:76
 Donner LR, 83:56
 Donné M, 80:83, 81:135
 Dooley TP, 83:155
 Dorliac P, 84:105
 Dorotinsky CS, 81:103
 dos Santos MJ, 81:66
 Drabkin H, 80:1
 Dreyling M, 83:46
 Droz J-P, 81:17
 Drwinga H, 81:24
 Dubinsky R, 83:115
 Durham JS, 80:165
 Dürst M, 85:105
 Duverger A, 80:47

 E
 Ebel T, 80:33
 Ebihara Y, 81:33
 Ebrahim SAD, 80:60
 Edwards M, 82:106
 Egan M, 83:111
 Egozcue J, 80:78, 84:123
 Eguchi T, 82:88
 Elder FFB, 80:138
 Elomaa I, 85:91
 Emerson J, 83:93
 Emerson S, 83:93
 Emi N, 83:37
 Emilia G, 80:95, 83:121
 Endo K, 80:155
 Erling MA, 79:92

 F
 Faccioli P, 79:123
 Fagioli F, 82:116
 Fan Y-S, 84:46
 Feig SA, 79:25
 Feigin M, 83:115, 79:153,
 85:118
 Fenger C, 82:82
 Fentiman IS, 83:111
 Ferrari MG, 80:95
 Ferro MT, 80:158
 Ferti A, 80:162, 81:169
 Feuerstein BG, 83:127
 Fick J, 82:106
 Fiori JM, 85:88
 Fitzgerald PH, 79:32
 Fletcher JA, 79:139, 84:76
 Flexor M, 79:130
 Florensa L, 81:185
 Forni A, 79:133
 Forus A, 82:151
 Fossati GS, 82:50
 Fotiou S, 80:103, 80:118
 Fouquet F, 80:47
 Fox M, 85:26
 Freireich EJ, 82:35
 Friedman E, 84:56
 Friedrichs W, 80:40
 Fuerst MP, 82:100
 Füzesi L, 84:85
 Fujimoto S, 85:5
 Fujimura T, 79:169
 Fukuhara O, 80:155
 Fults D, 81:118
 Funaki K, 79:54

 G
 Gaber E, 79:153
 Gabert J, 85:82
 Gadhia P, 83:172
 Gardner H, 83:5
 Gagel RF, 80:138
 Gaglielmelli T, 81:179
 Gagos S, 79:59
 Gandini G, 83:121
 Gangadharan VP, 83:71
 Gao Y, 79:149
 Garcia-Delgado M, 79:49
 Garcia-Miguel P, 83:160
 Garcia-Sagredo JM, 80:158
 Gardiner K, 80:1
 Gärtner F, 82:140
 Gascón F, 84:120
 Gasser TC, 82:163
 Gastaut JA, 85:82
 Gaudray P, 84:1, 84:9
 Genuardi M, 79:82
 Gershagen S, 83:105
 Geuna M, 81:179
 Geurts JMW, 79:1
 Gezer S, 79:86
 Ghali D, 83:5
 Giacobbi F, 83:121
 Giglio S, 80:80
 Giles FJ, 82:100
 Gilsbach JM, 79:144
 Gioanni J, 84:1, 84:9
 Gipsh N, 83:140, 85:1
 Gipson C, 85:20
 Giudiceandrea P, 79:82, 84:15
 Glassberg B, 80:172
 Glassman AB, 83:144
 Gnarr JR, 82:128
 Gnekow AK, 80:23
 Göbel U, 80:23
 Gockel A, 81:1
 Goguel A-F, 80:47
 Gohla G, 80:33
 Golden WL, 85:101
 Golladay ES, 80:20
 Gollin SM, 84:99
 Gómez AO, 82:67
 Gómez JAP, 82:67
 Gómez L, 81:173
 Goranova L, 82:146
 Gouw ASH, 84:95
 Grace C, 80:87, 82:9
 Graf N, 80:23
 Grafodatsky A, 81:144
 Granata P, 83:28
 Green AR, 80:87, 82:9
 Gregory A, 79:127
 Grellier P, 84:1
 Grierson HL, 80:124
 Griffin CA, 82:30
 Grimaldi DM, 81:66
 Gruppioni R, 80:167
 Gu L-J, 81:76
 Gualandi F, 80:167
 Guan X-Y, 80:55
 Guanciale Franchi P, 85:124
 Guerra AP, 82:67
 Guglielmelli T, 81:179
 Gullón A, 80:159, 83:119
 Gunawan B, 84:85
 Guselle JF, 84:24
 Gusterson BA, 81:166, 81:111

 H
 Haas OA, 83:5
 Hagemeijer A, 79:97
 Hägerstrand I, 81:135
 Haim S, 80:118
 Hajjar FM, 81:38
 Haller E, 81:158
 Hambraeus G, 80:86, 81:1,
 81:46
 Hammoudah S, 84:19
 Hammoudah SAFM, 79:15
 Hansen BH, 81:13, 85:68
 Hansen KB, 79:15
 Harbott J, 79:8, 80:23
 Hardan I, 83:140
 Harris M, 80:17
 Hartley AL, 80:17
 Hashimoto K, 81:56
 Hasle H, 79:79
 Hasumoto M, 81:175
 Hawkins AL, 82:30
 Hay RJ, 81:103
 Hayes KJ, 83:144
 Hecht BK, 84:1, 84:9, 85:157
 Hecht F, 80:171, 84:1, 84:9,
 85:157
 Hedges LK, 85:51
 Heide G, 79:144
 Heim S, 79:157, 80:83, 80:86,
 80:103, 80:110, 81:46,
 81:135, 82:82, 82:175
 Heimann P, 85:138
 Heinrich SD, 81:94
 Heinz R, 80:129
 Helander T, 79:21
 Hellmann A, 83:75
 Henn W, 79:144
 Heppell-Parton AC, 81:1
 Hernandez JM, 82:17
 Hernandez-Martí MJ, 83:82
 Hernández-Moneo JL, 83:160
 Herrmann ME, 85:20
 Hess M, 80:124
 Hidajat M, 82:80
 Higashi M, 85:5
 Hill D, 82:23
 Hindkjaer J, 79:15, 84:19
 Hiorns IR, 83:136
 Hirabayashi Y, 81:33
 Ho S, 81:42
 Hoekstra HJ, 84:27
 Holbrook T, 79:115
 Hollings PE, 79:32
 Holloway T, 80:87, 82:9
 Hølund B, 80:110
 Hoo JJ, 79:127
 Horikawa I, 85:97
 Horiuchi A, 81:20
 Horsman DE, 80:165, 82:85
 Huang Q-H, 81:76
 Huang W, 81:76
 Hulseberg D, 82:93
 Husain SA, 80:115

 I
 Iatridou-Kyrkou K, 79:59
 Iavarone A, 82:106
 Ikeda H, 79:89
 Ikeuchi T, 81:33
 Imamura T, 85:5
 Imieliński B, 85:61
 Inazawa J, 81:20
 Invernizzi R, 80:80
 Irimajiri K, 81:20
 Ishida T, 81:33
 Israel MA, 82:106
 Issa B, 84:113
 Itoyama T, 81:175
 Iwabuchi A, 79:169
 Izutsu T, 83:84

 J
 Jackson P, 81:166
 Jacrot M, 80:47
 Jagannath S, 82:41
 Jämsch W, 79:173
 Jeniroba D, 82:23
 Jensen PD, 79:15
 Jin C, 82:175
 Jin Y, 79:157, 81:46, 82:175
 Johansson B, 82:146
 Johansson L, 80:85, 81:46
 Johansson M, 80:56, 81:46,
 83:176
 Jones B, 79:127
 Jones E, 81:118, 85:143
 Joseph-Lerner N, 79:153
 Joshi V, 79:115
 Juan JL, 82:67
 Julia SF, 85:51

 K
 Kadin ME, 80:13
 Kakazu N, 81:20
 Kalmantis T, 84:91
 Kaltoft K, 81:13, 85:68
 Kameoka J, 80:155
 Kamura T, 85:5
 Kaneko T, 83:42
 Kang Y-S, 79:74, 85:43
 Kannourakis G, 83:12
 Kao Y, 80:75
 Kao YS, 80:20, 81:94
 Karakitsos P, 79:59
 Karaiskos C, 80:103, 80:118
 Karl MC, 84:85
 Kasak ME, 83:160
 Kashima K, 81:83
 Kashuba V, 80:1
 Kashuba VI, 81:144
 Kasprzyk A, 85:37
 Kato H, 83:37
 Katz R, 82:23
 Kavanagh J-J, 85:43

- Kawakubo K, 79:169
Kawashima K, 83:37
Kazmierczak B, 79:1
Kearney L, 79:97
Kelsen DP, 81:139
Kelsey AM, 80:17
Kenet G, 83:140
Kessler CE, 82:100
Ketter R, 81:109
Keung Y-K, 80:135
Khokhar MT, 83:18
Kim B-A, 85:43
Kim B-G, 79:74
Kingsley KL, 81:99
Kintzel D, 79:173
Kishimoto T, 79:89
Kissin MW, 81:166
Kitano K, 84:69
Kitaori K, 83:37
Klein A, 85:118
Klein G, 81:144
Kler RS, 80:115
Klimek A, 85:155
Knoll JHM, 80:13
Knuth A, 80:138
Knutsen T, 82:128
Knuutila S, 79:21, 84:73, 85:91
Kobayashi H, 83:46, 84:69
Kobayashi M, 82:54
Koch J, 79:15, 84:19
Koehler A, 84:39
Kojima T, 81:33
Konishi T, 83:42
Konstantakopoulos S, 83:12
Kools PFJ, 79:1
Kovar H, 83:5
Kozmierczak B, 79:1
Kreichberg A, 81:173
Kreiner G, 80:129
Krichevsky S, 81:115
Krishnan Nair M, 83:71
Kuang S-Q, 81:76
Kubonishi I, 82:54, 82:88
Kudo T, 83:84
Kullendorff C-M, 80:83, 81:135
Kundi M, 80:129
Kusak ME, 83:160
Kusuanco DA, 82:100
Kwong YL, 80:72, 80:82, 81:28, 81:92, 82:70, 82:76, 83:1, 85:159
Kyrouti A, 79:59
- L
La Starza R, 79:182
Lai KN, 81:42
Lai KY, 82:73
Lafage-Pochitaloff M, 85:82
Lalkin A, 85:118
Lamberti L, 79:133
Lampel S, 81:109
Lampert F, 79:8, 80:23
Lando C, 79:133
Lang S, 83:5
Laraña J, 80:158
Larramendy ML, 79:21
Larrañaga HJA, 85:16, 85:88
Lasota J, 81:24
Lathrop JC, 80:150
Latronico AC, 79:36
Lawrence GN, 82:100
Leana-Cox J, 82:93
Leavitt SA, 83:93
- Le Beau MM, 83:46
Leblanc T, 79:130
Le Coniat M, 79:130, 79:186
LePaslier D, 81:1
Lee E-D, 79:74, 85:43
Lee FY, 84:60
Lee J-H, 79:74, 85:43
Lee K-H, 79:74, 85:43
Lee S, 82:100
Lee S-H, 79:74
Lehmann K, 79:173
Lentini R, 84:15
Leonard NJ, 80:29
Leone PE, 83:160
Leong SP, 80:168
Leong SPL, 83:93
Leuschner E, 80:33
Lewis FR Jr, 85:20
Leytin V, 85:118
Li MY, 80:63
Li PKT, 81:42
Li YS, 84:46
Liang BC, 80:55
Liang R, 85:159
Liberski PP, 85:81, 85:155
Lim SW, 82:100
Limon J, 83:75, 85:61
Lin D-T, 84:60
Lin K-H, 84:60
Lin M-T, 84:60
Lindholm J, 79:119
Linehan WM, 82:128
Liosi A, 79:59
Lippitz B, 79:144
Lishner M, 79:153, 83:115, 85:118
Liu MC, 84:60
Liu S, 82:128
Livdi E, 79:82
Llombart-Bosch A, 85:113
Longo G, 80:95
Looijenga LHJ, 85:133
Look RM, 82:100
López-Ginés C, 85:113
Loukopoulos D, 80:68, 84:91
Louwagie A, 82:80
Lowery M, 84:113
Lozanova T, 79:173
Lu D, 79:149
Lubiński J, 83:75
Ludkovsky O, 81:115
Lumadue JA, 82:30
Lux A, 81:1
- M
Ma MS, 80:63
Ma SK, 81:28, 82:73
Machavoine C, 81:17
Machii T, 84:69
Machinami R, 81:33
Macy ML, 81:103
Madhavan J, 83:71
Maeda T, 83:127
Maekawa T, 81:20
Maffei L, 84:15
Magdalinaki A, 81:24
Magnani I, 79:97
Malcolm AJ, 80:107
Malet P, 82:170, 85:58
Malliaros S, 81:169
Malone JM, 81:125
Mandahl N, 79:119, 79:157, 80:83, 80:85, 81:46, 81:135, 82:146, 83:32
- Mandel M, 83:140
Mann G, 83:5
Manor Y, 79:15, 83:115, 85:118
Marasca R, 80:95
Mariani T, 85:78
Marin J, 80:160, 83:119
Mark HFL, 80:150
Mark J, 79:188
Mark Z, 83:140
Marks DI, 81:24
Marosi C, 80:129
Martelli MF, 79:182
Martin RH, 80:29
Martin-Henao GA, 79:177
Maserati E, 80:80
Masi M, 79:8, 84:15
Mathew S, 81:139
Matsuoka A, 83:37
Mattarelli G, 82:163
Mattern VL, 83:155
Matteucci C, 79:182
Matutes E, 83:18
Matzourani M, 80:68
May W, 79:25
Mayer JLR, 81:38
Mazzola D, 83:28
McConnell TS, 80:135
McGuire LJ, 81:103
Mead RS, 81:151
Mecucci C, 79:182, 82:17, 82:80, 83:25
Meeus P, 82:80, 83:25
Meguro K, 80:155
Mehta AB, 85:37
Meietis J, 84:91
Melamed J, 80:9, 82:62
Meloni AM, 79:92, 79:104, 79:136, 79:160, 80:168, 81:99
Meltzer PS, 80:55, 83:32
Mendonça BB, 79:36
Mensink HJA, 79:164, 84:95
Merlens F, 83:176
Meroni E, 83:28
Mertens F, 79:119, 79:157, 80:83, 81:135, 82:175, 83:176
Meuzelaar JJ, 82:161
Meytes D, 83:90
Michaelis SC, 81:1
Michaux J-L, 82:17
Michaux L, 82:17
Mihatsch MJ, 82:163
Miki T, 83:87
Mimitsulis C, 84:91
Minelli E, 83:28
Miranda JLG, 82:67
Miró R, 84:123
Misawa S, 81:83
Mitelman F, 79:119, 79:157, 80:83, 80:85, 81:46, 81:135, 82:146, 82:175, 83:32, 83:176
Miura AB, 81:56
Miura F, 81:56, 83:84
Miyoshi I, 82:54, 82:88
Moch H, 82:163
Modi W, 81:144
Mohamed AN, 80:60
Mohapatra G, 83:127
Molenaar WM, 82:57, 82:161, 84:27, 85:152
Mols R, 79:1
Mondello C, 79:41
- Montes C, 84:120
Moore CM, 83:155
Moreman P, 83:174
Morgan D, 80:135
Morgan R, 80:1
Morishita H, 79:89
Morizio E, 85:124
Morrison MJ, 79:70
Mozziconacci M-J, 85:82
Mor O, 84:56
Motokura T, 84:69
Mrózek K, 83:75, 85:61
Murakami T, 79:169
Musio A, 82:123, 85:78
Myklebost O, 82:151
- N
Nacheva E, 80:87, 82:9
Naem R, 79:139
Nagler A, 81:115
Nakagawa H, 81:83
Nakagawa M, 79:89
Nakai H, 81:83
Nakamura H, 81:175
Nakamura T, 83:65
Nakamura Y, 81:20
Nakano H, 85:5
Narita A, 84:69
Nastasi G, 82:50
Nebreda P, 83:160
Nedosztyko B, 83:75, 85:61
Negrini M, 83:65
Nelson MA, 83:93
Neri G, 79:82, 80:66
Neumann Y, 83:140
Nilbert M, 83:32
Nilsson A-S, 81:144
Nishida K, 79:8
Nishigaki H, 81:83
Nishiya I, 83:84
Nokagawa H, 81:83
Nordenskjöld M, 84:56
Notohamiprodjo M, 80:95
Novotna H, 82:163
Nowell PC, 81:24
Nowotny H, 80:129
Nuzzo F, 79:41
- O
Odero MD, 80:160, 83:119
Ogawa H, 79:89
Ogur G, 85:138
Ohyashiki JH, 79:169
Ohyashiki K, 79:169
Okamoto A, 85:97
Okamoto S, 81:175
Olde-Weghuls D, 82:140
Oliveros O, 82:155
Olopade OI, 83:46
Olson S, 83:93
Onderka E, 80:129
Oosterhuis JW, 79:164, 84:95, 85:133
Opalka B, 81:1
Orellana-Alonso C, 83:82
Ornellas MH, 84:32
Ortega JJ, 80:78
Oshimura M, 85:97
Ozisik YY, 79:136
- P
Padovani P, 79:133
Paetau A, 84:73
Pérez A, 81:185

- Palestro G, 81:179
 Palka G, 85:124
 Panani AD, 80:162, 81:169
 Pandis N, 80:103, 80:110, 80:118, 82:82
 Pangalis G, 84:91
 Pangalos C, 80:68, 85:75
 Panzer-Grümayer ER, 83:5
 Paolucci G, 79:123
 Papa G, 79:82, 80:66, 84:15
 Papaconstantinou C, 85:75
 Papadimitriou SI, 85:75
 Papageorgaki P, 79:59
 Papanastasiou C, 85:75
 Papasavas P, 84:91
 Paquis P, 84:9
 Paradise-Aldo S, 83:82
 Paridaens R, 82:103
 Park CH, 80:135
 Park K-B, 79:74, 85:43
 Park SH, 83:127
 Park S-Y, 79:74, 85:43
 Parlier V, 81:158
 Parrington JM, 85:26
 Pasquali F, 80:170
 Patel RK, 83:178
 Paterakis G, 80:68
 Pathak S, 79:59, 83:172
 Patil SR, 82:93
 Pavarino AC, 85:16
 Pazzi I, 82:116
 Pearson ADJ, 80:107
 Pedersen B, 79:15, 79:79, 84:18
 Pedersen CB, 81:13, 85:68
 Pedersen S, 85:68
 Pedeutour F, 85:157
 Pedone CA, 81:118
 Peier A, 79:104, 84:116
 Peier AM, 79:92, 80:168, 81:99
 Peila R, 85:124
 Pekarsky Y, 80:1
 Penchansky L, 84:99
 Pérez MM, 84:12
 Pérez Losada A, 81:185
 Perissel B, 82:170, 85:58
 Perlman EJ, 82:30
 Pestaña A, 81:173, 83:160
 Peters K, 80:13
 Petrovic V, 83:12
 Pfeleiderer C, 83:5
 Phelan C, 84:56
 Pinney D, 84:24
 Pirc-Danoowinata H, 80:129
 Poon ASY, 81:42
 Popescu NC, 80:100, 82:1
 Porenta G, 80:129
 Posekany K, 79:115
 Poteat HT, 84:76
 Poulos M, 81:182
 Poupon M-F, 80:47
 Pozzi E, 83:28
 Prados M, 82:106
 Prescher G, 80:40
 Previali R, 82:116
 Pruthi RK, 83:61
 Pucheri W, 84:32
 Puntoni R, 79:133
 Pylkkänen P, 84:73
 Pysker T, 84:113
- Q**
 Queizan A, 83:160
- R**
 Rabits PH, 81:1
 Radaskiewicz T, 83:5
 Rademaker AW, 80:29
 Radnay Y, 83:115
 Rainho CA, 81:66
 Rajasekharan Pillai G, 83:71
 Ramanakis K, 81:109
 Ramesh V, 84:24
 Ramond S, 83:165
 Ramsey DA, 84:46
 Rannani P, 83:140
 Rao PH, 81:139
 Raptis S, 80:162, 81:169
 Ratahak A, 80:124
 Ravid M, 79:153, 83:11, 85:118
 Rechavi G, 83:140, 84:56, 85:1
 Rege-Cambrin G, 81:179
 Reid MM, 80:107
 Reiter A, 80:23
 Renard M, 80:121
 Repa C, 85:75
 Repp R, 79:8
 Resino M, 80:158
 Reuter V, 80:9, 82:62
 Rey JA, 83:160
 Rezanka L, 80:100
 Ribeiro R, 84:32
 Riboni R, 79:41
 Righi R, 83:28
 Rigolin GM, 82:116
 Riley R, 79:115
 Rimessi P, 80:167
 Rios R, 84:120
 Ritterbach J, 79:8, 80:23
 Rivera H, 81:97
 Roberti G, 82:116
 Roberts M, 83:105
 Robinson ES, 83:155
 Roca OF, 82:67
 Rodriguez E, 80:9, 82:62
 Rogatto SR, 81:66
 Rohen C, 80:33, 84:82
 Rombos J, 84:91
 Rootman J, 82:85
 Rosenberg C, 79:36
 Rosenthal E, 83:140
 Rosman I, 79:32
 Rosner E, 83:140, 85:1
 Rowley JD, 83:46
 Roy SK, 83:178
 Rubnov V, 83:140
 Rundcrantz H, 79:188
 Rustgi AK, 84:24
 Ruutu T, 79:21
 Rydholm A, 83:32
 Ruff P, 81:182
 Rynditch A, 80:1
- S**
 Sabbioni S, 83:65
 Sacchi N, 79:97
 Sacchi S, 80:95
 Sadamori N, 81:175
 Saglio G, 81:179
 Sainty D, 85:82
 Saito H, 83:37, 84:69
 Saito M, 81:56
 Sakuragi N, 85:5
 Salvatore M, 83:28
 Salmon SE, 83:93
 Salvador J, 84:123
 Samson I, 82:103
 Sandberg AA, 79:92, 79:104, 79:136, 79:160, 80:1, 80:168, 81:99, 84:116
- Sanger WC, 80:124
 San Román C, 80:158
 Sans-Sabrafen J, 81:185
 Saragas E, 81:182
 Sarasa JL, 83:160
 Sariban E, 85:138
 Sarkar FH, 80:60
 Sasagawa I, 81:175
 Sasser EW, 82:90
 Satake Y, 83:42
 Sato A, 80:155
 Sauter G, 82:163
 Sawyer JR, 82:41, 83:168
 Sayli BS, 79:86
 Sbrana I, 79:133, 82:123
 Scabini M, 82:50
 Scappaticci S, 82:50, 84:89
 Scaravaglio P, 81:179
 Schad CR, 83:61
 Schiffer CA, 82:93
 Schlögl E, 80:129
 Schmidt PM, 81:158
 Schmidt S, 84:24
 Schmidtke K, 81:1
 Schneider BF, 85:101
 Schneider NR, 81:72
 Schoenmakers EFPM, 79:1, 84:82
 Schousboe K, 80:110
 Schramm A, 81:1
 Schreck RR, 82:100
 Schröder JM, 79:144
 Schütte J, 81:1
 Schwartz HS, 85:51
 Schwartz S, 82:93
 Sciadini MF, 85:51
 Sciort R, 79:189
 Seagon S, 85:105
 Seashore MR, 81:38
 Secker-Walker LM, 85:37
 Seiber S, 80:40
 Seghezzi L, 80:80
 Seitz G, 81:109
 Sen S, 82:35
 Sensi A, 80:167
 Seruca R, 82:140
 Seuáñez HN, 84:32
 Severi-Agular GDdeC, 85:88
 Seyger MMB, 80:23
 Sfikas K, 80:103, 80:118
 Shah PM, 83:178
 Sham C, 83:12
 Sharma S, 83:148
 Sharon N, 83:140
 Shashi V, 85:101
 Shekhter-Levin S, 84:99
 Shen M-C, 84:60
 Sherer ME, 84:99
 Shikano T, 83:42
 Shipley JM, 81:166, 83:111
 Shishido T, 80:155
 Shohat M, 83:90
 Siebert R, 81:1
 Sierrasesumaga L, 79:49
 Silva MLM, 84:32
 Silverman J, 79:115
 Simi S, 85:78
 Simões FV, 84:32
 Simonetti J, 85:82
 Simonitach I, 83:5
 Simpson S, 82:1
 Sin VC, 81:28
- Slater HR, 83:12
 Smith D, 81:1
 So AKL, 81:42
 Sobrinho-Simões M, 82:140
 Soda H, 81:175
 Sofer O, 85:1
 Soffer O, 83:140
 Sole F, 81:185, 84:120
 Sonoyama M, 84:69
 Spanier S, 79:104
 Speights VO Jr, 83:56
 Speleman F, 82:151
 Spina M, 82:50
 Spina P, 84:89
 Spurbeck JL, 83:61
 Staats B, 80:33
 Stamatiou M, 85:75
 Stamatiopoulos K, 80:68, 84:91
 Stanbridge EJ, 80:167, 81:144
 Stasi R, 80:66
 Stass SA, 82:35
 Stern C, 84:82
 Sterner C, 84:24
 Sternes KL, 79:64
 Stiebel H, 84:56
 Stoepker M, 85:133
 Stone JF, 84:116
 Störkel S, 79:164, 84:95, 85:152
 Strömblad L-G, 80:83
 Stul M, 82:80, 83:25
 Stuppi L, 85:124
 Sugawara T, 80:155
 Sugito S, 82:54
 Sugiyama H, 79:89
 Suikerbuijk RF, 82:140
 Sullivan BA, 82:93
 Summersgill BM, 81:166, 83:111
 Sundareshan TS, 84:51, 85:85
 Sureda A, 79:177
 Surti U, 79:136, 81:99
 Swansbury GJ, 83:136
 Szego K, 79:127
 Szeles A, 81:144
 Szymanska J, 85:91
- T**
 Tabak DG, 84:32
 Taetle R, 83:93
 Tajara EH, 85:16, 85:88
 Takai S, 83:87
 Takeo T, 83:37
 Talpos GB, 85:20
 Tam JSL, 81:42
 Tanaka S, 81:83
 Tang KC, 81:28, 82:70, 82:76
 Tanimoto M, 83:87
 Taniwaki M, 79:89, 81:83
 Tarkkanen M, 85:91
 Tateo H, 79:54
 Tateo S, 82:50
 Tefferi A, 83:61
 Temperani P, 80:95, 83:121
 Tho C, 83:168
 Terada N, 84:69
 Terrier-Lacombe M-J, 81:17
 Thestrup-Pedersen K, 81:13, 85:68
 Thiel G, 79:173
 Thomas JR, 83:168
 Thompson FH, 83:93
 Tien H-F, 84:60
 Timmons CF, 81:72

- Tiong T, 83:12
 Tobler A, 81:158
 Todt B, 81:1
 Tomassetti P, 79:123
 Tomlinson GE, 81:72
 Tomonaga M, 81:175
 Tone S, 79:89
 Tonk V, 81:72
 Torelli G, 80:95
 Torelli U, 83:121
 Toren A, 83:140
 Towatari M, 83:37
 Toyama K, 79:169
 Toyozumi H, 83:37
 Trabanelli C, 80:167
 Trakhtenbrot L, 85:1
 Trent JM, 80:55, 83:93, 84:129
 Tribalto M, 80:66, 84:15
 Trivedi AH, 83:178
 Tsao Ss-Y, 81:42
 Tserkezoglou A, 80:103, 80:118
 Tso SC, 82:76
 Tsuchiya T, 82:54
 Tukiainen E, 85:91
 Tuna M, 79:86
 Turc-Carel C, 84:1, 84:9, 85:157
 Tussell L, 80:78

 U
 Uberti J, 80:60
 Uchimaru K, 84:69
 Udayakumar AM, 85:85
 Uemora Y, 81:20, 82:88
 Ungar S, 81:1
 Urase F, 81:20
 Utsumi KR, 81:186
 Uyttebroek A, 80:121

 V
 Valenti L, 82:50
 Valle M, 84:120
 Vamos E, 85:138
 Van Baaren J, 82:57
 Van Brunt T, 80:20, 80:75

 Van Damme B, 79:189
 Van den Berg E, 79:164, 82:57, 82:161, 84:27, 84:9, 85:152
 Van Den Berghe H, 79:1, 79:189, 80:121, 82:17, 82:80, 83:174, 83:25, 84:128
 Vandenberghe P, 82:103
 van der Hout, 81:1
 Van de Ven WJM, 79:1, 84:82
 van Echten J, 82:57, 85:133
 van Gurp RJHLM, 85:153
 Van Hoof A, 82:80
 van Melle G, 81:158
 Van Orshoven A, 82:17, 82:103
 Van Roy N, 82:151
 Vaquero J, 83:160
 Vasilev SA, 79:160
 Vavourakis S, 80:68
 Vénuat A-M, 81:17
 Vecchio D, 79:133
 Veiga I, 82:140
 Venditti A, 79:82, 80:66
 Verdeguer-Miralles A, 83:82
 Verhoef GEG, 82:103
 Verma RS, 79:95
 Vermey A, 82:57
 Versteeg R, 82:151
 Vicente A, 84:120
 Vienna-Morgante AM, 79:36
 Vig BK, 79:64
 Vigié, 83:165
 Villa-Elizaga L, 79:49
 Villavicencio H, 84:123
 Viniou N, 80:68
 Viniou N-A, 84:91
 Virolainen M, 85:91
 Vogel S, 79:173
 von Ballestrem C-L, 81:109
 von Kap-herr C, 85:101
 Voullaire L, 83:12

 W
 Wagner U, 82:163
 Wald N, 84:99, 85:5

 Waldman FM, 82:163, 83:1278
 Waldron JA, 82:41
 Wang C-H, 84:60
 Wang DD, 84:116
 Wang M-R, 82:170, 85:58
 Wang N, 79:25, 83:10
 Wanschura S, 79:1, 84:82, 85:105
 Weaving A, 81:182
 Wedell B, 79:188
 Weinstein R, 83:93
 Weisenburger DD, 80:124
 Wellss D, 85:26
 Wenger SL, 85:72
 Wennerberg J, 79:157, 82:175
 Werner M, 81:115
 Wernicke C, 79:173
 Whang-Peng J, 82:128
 Wharton JT, 85:43
 White N, 80:87
 White VA, 82:85
 Wijsman J, 79:97
 Wiklund T, 85:91
 Wiley J, 79:115
 Wiley JE, 82:90
 Willers C, 81:1
 Williams BJ, 81:118, 85:143
 Wilson GD, 79:111
 Wilson KS, 81:72
 Winberg G, 81:144
 Witkowski R, 79:173
 Wlodarska I, 82:17, 82:80
 Woessner S, 81:185
 Wollman MR, 84:99
 Wolman SR, 80:60
 Wong KF, 80:72, 81:28, 81:92, 82:70, 82:73, 82:76, 83:1, 83:144, 85:89
 Wong TK, 80:72, 81:92
 Woodruff K, 79:25
 Wooldridge L, 80:124
 Wooldridge TN, 80:124
 Wu G, 83:105
 Wullich B, 81:100

 X
 Xofteri I, 84:91
 Xiao S, 79:139
 Xie X, 79:149
 Xu J, 83:105
 Xu L, 84:24
 Xue Y, 79:149

 Y
 Yamada K, 83:87
 Yamada M, 79:54
 Yamashiro T, 82:54
 Yarkoni S, 85:118
 Yatanagas X, 80:68, 84:91
 Yehuda O, 81:115
 Yokota J, 85:97
 Yoshida MA, 81:33
 Yunes A, 82:23
 Yule SM, 80:107
 Yunis E, 82:155

 Z
 Zabarovsky E, 80:1
 Zabarovsky ER, 81:144
 Zachée P, 82:103
 Zajgaczek S, 83:75
 Zalberg IQ, 84:32
 Zalupski M, 79:104
 Zamarrón A, 84:123
 Zang KD, 79:144, 81:109
 Zetterberg A, 81:173
 Zhang T, 81:76
 Zhao J-F, 83:148
 Zhao RZ, 80:63
 Zhao WP, 82:128
 Zhou H, 82:35
 Zhu D, 80:63
 Zhu XL, 81:118
 Zimonjic DB, 80:100, 82:1
 Zittoun R, 83:165
 Zollino M, 80:66
 Zordroger H, 84:27
 Zoubek A, 83:5
 Zombos N, 84:91
 zur Hausen H, 85:105



Subject Index to CGC Volumes 79–85

Acute erythroleukemia (M6)

constitutional dup(1q) in case, 80:82
in germ cell tumors, 79:25

Acute lymphatic leukemia; see Acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL)

ALL in patient with familial der(4), 82:90
B-ALL, 79:8
childhood type, 79:8
chromosome changes, 80:129; 83:90
chromosome painting, 84:19
chromosome 8, 79:8
early pre-B cell ALL, 82:88; 83:46
FISH studies, 79:8, 83:46; 85:37
FISH studies of 9p-, 83:46
i(14q) in T-ALL, 80:78
in germ cell tumors, 79:25
in XYY male, 84:157
inv(14q) in B-ALL, 80:72
jumping translocations in ALL, 80:80
molecular studies after BMT, 85:124
molecular studies in T-ALL, 84:32
molecular translocations in T-ALL, 84:138
partial trisomy 7 in child with, 84:19
PCR in T-ALL with SIL-TAL-1 fusion gene, 81:76
phorbol in cytogenetic preparations, 80:129
Ph+, 79:32; 81:83
Ph+ ALL with 14q+, 81:83
pre-B ALL, 83:46
PRINS study, 84:19
SCE levels in, 79:86
SIL/TAL1 recombination in ALL and lymphoma, 85:159
single cell trisomy, 85:37
T-ALL, 79:177; 81:76; 83:46; 84:32
t(1;14)(p34;q11) and +8 in T-ALL, 79:177
t(1;22)(q11;p11) in pre-B ALL, 82:88
t(2;14)(p13;q32) in CD10+, CD13+ ALL, 83:140
t(5;15)(p15;q13-15) in boy, 83:90
t(11;14)(p13;q11) in T-ALL, 84:32
variant Ph, der(9) and der(19), 80:162
XYY male with ALL, 83:178; 84:157
YAC probes for 9p-, 83:46
+4 in B-ALL with biphenotypia, 80:66
14q+ in ALL, 81:83
20q- in Ph+ ALL, 79:32

Acute megakaryoblastic leukemia (M7)

der(1;15)(q10;q10) in, 83:144
in germ cell tumors, 79:25
t(11;14)(p13;q11) in, 83:42

Acute minimally differentiated leukemia (M0)

cytogenetics, 80:66
+4 in, 80:66

Acute monoblastic leukemia; see Acute monocytic leukemia

Acute monocytic leukemia (M5)

biclonal, 82:70
chromosome changes in, 82:70
congenital with t(5;6)(q31;q21), 81:38
in germ cell tumor, 79:25
spontaneous remission, 81:38
tetrasomy 8, 79:182
translocations in, 82:76
t(3;11)(q21;q13) in M5B, 83:119

t(8;21)(q22;q22) in M5a, 79:82
7q- and +9, +22 in, 82:70
11q23 in, 82:76

Acute myeloblastic leukemia (M1)

t(3;11)(q21;q13) in, 83:119

Acute myeloblastic leukemia (M2)

chromosome changes, 79:130
molecular studies in, 83:37
tetrasomy 8, 79:182
with 9p-, 83:46
t(2;3)(p22;q28) in, 79:130
t(7;11) in AML followed by eosinophilia and chromosome 5 changes, 83:37
+4 with double minutes, 83:165
+5 in, 84:120

Acute myeloid leukemia (AML); see Acute non-lymphocytic leukemia (ANLL)

Acute myelomonocytic leukemia (M4)

in germ cell tumors, 79:25
isochromosome 4p, 79:127
i(4p), 79:127
prognosis and i(4p), 79:127

Acute non-lymphocytic leukemia (ANLL)

biclonal, 85:1
blast size and karyotype, 83:1
CGH studies, 82:9
chromosome changes, 79:130, 84:60
clinical aspects and cytogenetics, 84:60
correlation of cytogenetic and other features, 84:60
FISH studies in AML, 83:1
hexasomy 8 and trisomy 11 in ANLL, 85:1
hyperdiploid AML, 83:1
in germ cell tumors, 79:25
molecular studies, 84:60
molecular studies after BMT, 85:124
N-ras in, 84:60
SCE levels in, 79:86
single cell trisomy, 85:37
study in Taiwan, 84:60
translocations in, 80:23
+4 and its meaning, 79:186
+4 with double minutes, 83:165
+5 in AML, 84:120
12q13, recurrent breakpoint in ANLL, 80:23

Acute promyelocytic leukemia (APL)

eight-way variant t(15;17), 83:136
FISH studies, 80:95; 83:136
molecular studies, 84:91
PML/RARa by PCR, 84:91
PML-RARa fusion transcript in Ph+ leukemia without t(15;17), 80:95
responsive to retinoid acid, 80:160
RT-PCR studies, 84:91
t(1;6;7;6;17;15;12;3) in APL, 83:136
t(14;17)(q22;q21) in, 80:160
variant t(15;17), 83:136
with APL phenotype but lacking t(15;17), 80:95

Adenomas

colon with +7, 82:82
pituitary, 84:89
salivary gland, 79:1

- Adenomyosis**
chromosome analysis, 80:118
del(7q), 80:118
uterine, 80:118
- Adipose tissue tumors**
FISH studies, 84:144
gene amplification, 84:144
molecular analysis, 84:144
- Adrenal gland**
chromosome changes, 79:36
FISH of cell line, 79:36
tumor cells in culture, 79:36
- Adult T-cell Leukemia (ATL)**
inv(10)(q11q24) in, 81:175
translocations in, 81:186
- Alveolar soft part sarcoma**
chromosome changes in, 81:94; 82:57
+ 8 in, 81:94
17q25 in, 82:57
- Angiomyxoma**
chromosome change, 84:156
karyotype of, 84:146; 156
MAR region involvement, 84:146
of vaginal wall, 84:156
- Animal tumors**
chromosome changes in spontaneous leiomyosarcoma, 79:54
melanoma in opossum, 83:155
rat thyroid, 80:138
uterine leiomyosarcoma in Chinese hamster, 79:54
- Apoptosis; see Programmed cell death**
- Ascitic fluid**
FISH studies, 84:116
malignant vs nonmalignant, 84:116
- Astrocytoma**
anaplastic, 81:125
cerebellar (pilocytic), 81:125
cerebral (pilocytic), 81:125
chromosome changes, 81:125; 82:168; 85:61
chromosome 8 changes, 81:125; 83:168
complex chromosome 8 changes, 83:168
molecular studies, 82:106
- Award Presentation**
Dr. Van den Berghe's speech, 84:128
to Dr. Sandberg, 84:128
- BCR/ABL fusion**
FISH of, 80:60
fusion detected in Ph-negative CML, 80:60
in ALL with 14q+, 81:83
M-bcr/abl fusion, 80:60
- Benign tumors**
mesenchymal, 84:133
molecular studies, 84:133
- Bile duct carcinoma**
chromosome changes, 84:159
distal common duct, 84:159
- Bladder**
chromosome changes, 82:170
chromosome changes in small cell carcinoma, 79:111
cytogenetics, FISH and CGH in cell line, 84:151
ectopic NOR in cancer, 85:129
ectopic NOR in leiomyosarcoma, 85:129
FISH studies, 82:163, 170
FISH studies of - Y, 82:163
molecular studies in cancer, 82:163
p53 expression in small cell carcinoma, 79:111
- Y in cancer, 82:163
- Bloom syndrome**
chromosome 15, 80:167
complementation of phenotype by chromosome 15, 80:167
- Bone marrow**
serial studies, 84:148
status and disease progression, 84:148
- Bone marrow transplantation (BMT)**
hematopoietic chimerism, 85:124
molecular studies in, 85:124
PCR amplification of DNA, 85:124
- Bowen's disease**
squamous cell carcinoma of vulva, 84:159
11p changes, 84:159
- Brain tumors**
allelic status of chromosome 1, 83:160
chromosome 7, 84:73
constitutional p53 mutations in, 82:106
cytogenetics, FISH and CGH in tumors, 84:133
ependymomas, 79:173
ganglioglioma, 85:155
glioblastoma, 81:118
microsatellite repeats, 84:56
pediatric, 81:125, 84:56
sex chromosome loss in benign and malignant tumors, 84:157
1p - in tumor, 83:160
- Breakpoint studies**
in salivary gland adenoma, 79:1
of t(1;16), 79:15
3q21 in hematologic disorders, 80:1
12q13 in ANLL, 80:23
- Breast**
additional 1q in phyllodes tumor, 83:111
amplified cDNA from 20q in cancer, 84:136
cancer, 80:33
carcinogenesis and cytogenetics, 84:135
chromosome changes in cancer, 80:33; 81:66; 84:135
chromosomes in benign and cancer lesions, 84:155
complex dynamics of karyotype, 84:137
cytogenetics and molecular variations in cell lines, 84:140
cytogenetics of ductal cancer, 84:155
cytogenetics of male cancer, 81:66
ectopic NOR in cancer, 85:129
familial cancer, 84:155
genetic events in cancer, 84:133
genetic evolution by CGH, 84:134
hamartoma, 84:82
HER-2/neu in early detection, 84:129
in-situ breast tumors, 84:155
male cancer, 81:66
nodular fasciitis, 81:166
phyllodes tumor, 83:111
RER+ phenotype, 84:155
single cell aberrations, 80:33
+ 8 and + 18 in, 80:33
20q13 amplicons and prognosis, 84:137
- Burkitt neoplasms**
translocation (8;22)(q24;q11) in multiple myeloma, 82:100
- Cancer**
cell cycle, 84:137
childhood cancer and multiple lipomatosis, 80:17
chromosome changes in lymphocytes and cancer, 79:133
predictive changes, 79:133
- Carcinoid**
cytogenetics, 84:95
in horseshoe kidney, 84:95
studies of, 84:95
- Cardiac myxoma; see Myxoma**
- Cell lines**
cervical cancer, 82:1
CML lines, 82:35
colorectal cancer, 81:103
HeLa, 85:97
keratinocyte, 85:105

- lung cancer, 80:47; 84:39
- molecular studies in HeLa, 85:97
- neuroblastoma, 82:151
- thyroid tumors, 80:138
- Centromere**
 - association in prostate cancer, 85:143
 - chromosomes 9 and 17, 85:143
 - spreading and aberrations in ovarian tumors, 80:63
- Cervical carcinoma**
 - cell lines, 82:1
 - cytogenetics of cell lines, 82:1
 - FISH in management, 84:151
 - genetic events, 84:133
 - LOH in, 79:74
 - molecular studies, 79:74; 82:1
 - papillomavirus negative, 82:1
 - uterine, 79:74
 - 17p in, 79:74
- Chinese hamster; see Animal tumors**
- Chondrosarcoma**
 - cytogenetics of mesenchymal, 83:56
 - cytogenetics of myxoid, 84:146
 - extraskeletal, 81:33
 - FISH analysis, 84:146
 - mesenchymal, 83:56
 - myxoid type, 81:33, 84:146
 - t(9;22)(q22;q12), 81:33
- Chordoma**
 - cytogenetics, 85:51
 - FISH study, 84:152
 - lumbosacral, 85:51
 - sacral, 84:152
 - telomerase in, 85:51
 - telomere, 85:51
- Choriocarcinoma**
 - chromosome changes, 80:9
 - FISH studies, 80:9
 - 12p painting, 80:9
- Choroid plexus tumors**
 - karyotype, 80:83
 - papilloma, 81:125
 - recurrent chromosome changes, 80:83
 - 22 in papilloma, 81:125
- Chromosomal microdissection**
 - application, 80:55
 - technique, 80:55
 - use in gene amplification studies, 80:55
- Chromosome**
 - chromosome changes in RCC, 82:128
 - chromosome 1 in brain tumors, 83:160
 - chromosome 1 in endometrial cancer, 81:109
 - chromosome 6 in lymphoma, 81:56
 - chromosome 7 in Wilms tumor, 79:92
 - chromosome 8 childhood ALL and NHL, 79:8
 - chromosome 9 in ALL, 83:46
 - chromosome 12 in choriocarcinomas, 80:9
 - chromosome 12 in germ cell tumors, 79:25; 82:62
 - chromosome 12 in ovarian germ cell tumor, 82:62
 - chromosome 12 in salivary adenoma, 79:1
 - chromosome 14 in ALL, 81:56
 - chromosome 17 and p53 in CML, 82:35
 - chromosome 18 in soft-tissue tumors, 84:76
 - chromosome 19 amplification in hematologic disorders, XX:XX
 - chromosome 22 in ependymomas, 79:173
 - chromosomes 1, 8, 11, 12, 15 and 17 in adrenal tumor cells, 79:36
 - chromosomes 3 and 7 in RCC, 82:128
 - chromosomes 5 and 16 in xeroderma pigmentosum fibroblast clone, 79:41
 - chromosomes 14 and 22 in meningioma, 85:101
 - hexasomy of chromosome 8 in ANLL, 85:1
- Chromosome changes**
 - in ALL, 80:129
 - in ANLL, 79:130
 - in brain tumors, 81:125
 - in breast cancer, 80:33
 - in childhood ALL and NHL, 79:8
 - in choriocarcinomas, 80:9
 - in chordoma, 85:51
 - in desmoid tumors, 79:139
 - in endometrial cancer, 80:110
 - in ependymomas, 79:173
 - in gastric and esophageal cancer, 81:139, 169
 - in germ cell tumors, 79:25
 - in glioma, 84:1, 9; 85:61
 - in immunoblastic lymphoma 79:59
 - in intermediate lymphoma, 79:89
 - in leiomyomas, 80:103
 - in liposarcoma, 79:104
 - in lung cancer cell lines, 84:39
 - in lymphomas, 80:129; 81:56
 - in MDS, 82:17
 - in meningioma, 79:146; 85:91
 - in MFH, 79:119, 85:101; 113
 - in multiple myeloma, 82:41, 83:71
 - in renal cell carcinoma, 82:128
 - in renal oncocytomas, 79:164
 - in retinoblastoma, 82:155
 - in salivary adenoma, 79:1
 - in sarcoma, 84:27
 - in squamous cell cancer of lung, 81:46
 - in stomach cancer, 81:169
 - in thyroid tumors, 80:138
 - in uveal melanoma, 80:40
- Chromosome-directed therapy**
 - clinical trial design, 84:130
- Chromosome microdissection**
 - admin from a colon cancer, 84:142
 - DNA sequences in ovarian cancer, 84:143
 - genomic alterations, 84:136
 - in cancer cells, 84:136
 - library of distal 15q, 84:142
 - marker chromosomes in gastric cancer, 84:142
 - of a breast cancer cell line, 84:136
 - of follicular lymphoma with 6q11 change, 84:142
 - of HSR, 84:136
 - origin of chromosome changes, 84:137
- Chromosome painting**
 - in ALL, 84:19
 - in childhood ALL and NHL, 79:9
 - in MDS, 82:17
 - in t(1;16), 79:15
- Chronic lymphocytic leukemia (CLL)**
 - bcl 1, 2, and 3, 85:118
 - chromosome changes, 83:121
 - EBV infection does not correlate with + 12, 82:80
 - FISH studies, 85:118
 - Richter, 83:121
 - telomere changes, 83:121
 - trisomy 12 (+ 12), 82:80
- Chronic myelocytic (myeloid) leukemia (CML)**
 - bcr/abl fusion detection, 80:60; 81:115
 - BCR/ABL in Ph-negative CML, 81:115
 - BCR translocation in Ph-negative CML, 85:82
 - blast crisis in, 79:21; 83:121
 - cell lines, 82:35
 - chromosome changes, 83:121
 - chromosome changes in transformation 81:182, 83:121
 - chromosome 17 and p53 mutations, 82:35
 - clonal evolution, 81:182
 - cytogenetics and remission rate, 84:15
 - FISH in Ph-negative CML, 80:60; 81:115
 - FISH studies of complex changes, 82:93

- FISH studies of neutrophils and lymphocytes, 83:61
 in germ cell tumors, 79:25
 interferon therapy, 84:15
 lack of correlation with breakpoint in M-BCR, 84:105
 molecular studies, 82:35
 NK cells in, 79:21
 PCR studies after BMT, 85:124
 Ph-negative cells with +8 during interferon therapy, 81:20
 Ph-negative CML and BCR, 85:82
 prognosis and p53, 84:105
 p53 in blast crisis, 82:35
 p53 in CML, 84:105
 transformation into acute leukemia, 81:182
 t(2;9;14;22) Ph-translocation, 80:155
 t(11;14)(q13;q32) in cells of Ph+ CML, 81:24
 variant Ph chromosomes, 82:93
- Chronic myelogenous leukemia; see Chronic myelocytic leukemia (CML)**
- Chronic myeloid leukemia; see Chronic myelocytic leukemia (CML)**
- Chronic myelomonocytic leukemia (CMML)**
 FISH studies, 80:87
 20q- in, 80:87
- Clinical correlations**
 chromosomes and breast cancer, melanoma and ovarian cancer, 84:135
 chromosomes 1 and 7, 85:75
 cytogenetic changes, 85:75
 t(5;18) in, 85:89
- Clonal evolution**
 in CML, 81:183
 in squamous cell carcinoma, 79:156
- Colon**
 adenoma, 82:82
 +7 in adenoma, 82:82
- Colorectal cancer**
 cell lines, 81:103
 chromosome changes, 81:103; 84:135
 effects of agents on RAS mutations, 84:149
 genetic origin, 81:103
 mutations of p53 in rat cancers, 84:149
 NF-2 gene in, 82:24
 pathogenetic heterogeneity, 84:135
 RAS mutations, 84:144
- Comparative genomic hybridization (CGH)**
 amplification, 80:55
 DNA sequence copy number, 84:138
 gene amplification in pediatric solid tumors, 84:150
 in AML, 82:9
 in bladder cancer, 84:151
 in breast cancer, 84:134
 in gastric cancer, 82:140
 in hematologic disorders, 84:151
 in prostate cancer, 84:131
 in thyroid tumors, 84:134
 Langerhans cell histiocytosis, 84:150
 methodology, 80:55; 82:140
 statistical method of analysis of profiles, 84:150
 studies of gene amplification, 80:55; 82:140
- Congenital agranulocytosis**
 evolution to MDS and basophilic leukemia, 84:99
 G-CSF therapy, 84:99
 -7 and +21 in, 84:99
- Constitutional changes**
 in pediatric cancer, 84:157
 mosaic +8 in MDS, 79:79
 mosaic +8 in trophoblastic disease, 80:150
 p53 changes, 82:106
 p53 changes and brain tumors, 82:106
 XXY and paraganglioma, 84:157
 XYY male and ALL, 84:157
 XYY male and Wilms tumor, 84:157
- Congenital leukemia**
 spontaneous remission, 81:38
 t(5;6)(q31;q21) in, 81:38
- Cytogenetic changes**
 in ALL, 80:129
 in ANLL, 79:130
 in brain tumors, 81:125
 in breast cancer, 80:33
 in childhood ALL and NHL, 79:8
 in choriocarcinomas, 80:9
 in chordoma, 85:51
 in desmoid tumors, 79:139
 in endometrial cancer, 80:110
 in ependymomas, 79:173
 in gastric and esophageal cancer, 81:139; 169
 in germ cell tumors, 79:25
 in glioma, 84:1, 9; 85:61
 in immunoblastic lymphoma, 79:59
 in intermediate lymphoma, 79:89
 in leiomyomas, 80:103
 in liposarcoma, 79:104
 in lung cancer cell lines, 84:39
 in lymphomas, 80:129; 81:56
 in MDS, 82:17
 in meningioma, 79:146; 85:91
 in MFH, 79:119; 85:101, 113
 in multiple myeloma, 82:41; 83:71
 in renal cell carcinoma, 82:128
 in renal oncocytomas, 79:164
 in retinoblastoma, 82:155
 in sarcoma, 84:27
 in salivary adenoma, 79:1
 in squamous cell cancer of lung, 81:46
 in stomach cancer, 81:169
 in thyroid tumors, 80:138
 in uveal melanoma, 80:40
- Deletions**
 in breast cancer, 80:33
 in lung cancer, 81:46
 in lung cancer cell lines, 84:39
 in lymphoma, 81:56
 in uveal melanoma, 80:40
 1p36.2-3 in neuroblastoma, 84:132
 1p- in brain tumors, 83:160
 3q- in gastric and esophageal cancer, 81:139
 5q- syndrome in child, 80:121
 6q- in liposarcoma, 79:104
 6q- in squamous cell carcinoma of parotid, 79:157
 6q- in stomach cancer, 81:169
 7q- in leiomyomas, 81:99
 7q- in uterine adenomyosis, 80:118
 9p- in glioblastoma, 83:127
 12q- (interstitial) in MDS, 80:158
 20q- in ALL (Ph+), 79:32
 20q- in MDS and MPD, 80:87
- Derivative chromosomes**
 der(1) in leiomyoma, 79:136
 der(1) in MFH, 79:119
 der(6)t(1;6)(q11;p11) in lymphoma, 79:59
 der(8) in MFH, 79:119
 der(14) in MFH, 79:119
 familial der(4) in case of ALL, 82:90
 in breast cancer, 80:33
 in endometrial cancer, 80:110
 in ependymomas, 79:173
 in lung cancer, 80:46
 in uveal melanoma, 80:40
- Dermatofibrosarcoma protuberans**
 cytogenetic changes in, 80:75
 in child, 80:75

- rearrangements of 17 and 22, 84:145
- 46,XY,t(X;7) in, 80:75
- Desmoid tumors**
 - chromosome changes, 79:139
 - jumping translocation, 84:141
 - retroperitoneal, 84:141
 - + 8 in recurrence, 79:139
- Dicentric chromosome**
 - in xeroderma pigmentosum fibroblast clone, 79:40
 - 5p and 16q in dicentric, 79:40
- DNA**
 - content in NHL, 80:124
 - flow cytometry measurement in NHL, 80:124
- Double minute chromosomes (dmin)**
 - in brain tumors, 81:125
 - in gastric cancer, 82:140
 - in lymphocytes of tumor cases, 82:50
 - in MDS, 79:169
 - in meningioma, 79:147
 - in MFH, 85:91
 - in multiple myeloma, 82:41
 - in renal cancer, 80:168
 - microdissected from a breast cancer cell line, 84:136
 - + 4 and double minutes in AML, 83:165
- Duodenum**
 - Adenocarcinoma, 82:146
 - clonal heterogeneity, 82:146
 - cytogenetics, 82:146
 - translocations, 82:146
- Endodermal sinus tumors**
 - childhood, 84:147
 - 1p - in, 84:147
- Endometrial cancer**
 - cell line, 84:152
 - chromosome 1, 81:109
 - cytogenetics of early stages, 80:110
 - FISH studies, 80:110, 81:109
 - near-diploid karyotypes, 80:110
- Endometrial polyps**
 - cytogenetics, 84:151
 - subgroups, 84:151
- Endometrial stromal sarcoma**
 - chromosome changes, 84:85
 - mixed phenotype, 84:85
- Eosinophilia; see Hypereosinophilia**
- Ependymomas**
 - chromosome 22, 79:173
 - cytogenetic changes, 79:173
 - FISH studies, 79:173
- Erythroleukemia (M6)**
 - chromosome changes in, 85:85
 - sole changes in, 85:85
 - tetrasomy 21 in, 85:85
- Esophageal cancer**
 - chromosome changes, 81:139, 82:175
 - hsr at 11q13, 82:175
 - squamous cell carcinoma, 82:175
 - 3q - as primary change, 81:139
- Essential thrombocythemia (ET)**
 - in germ cell tumors, 79:25
 - 20q - in, 80:87
- Ewing tumor**
 - after treatment of anaplastic lymphoma, 83:5
 - FISH studies, 84:147
 - interphase FISH, 84:147
 - molecular studies, 83:5; 84:147
- Familial disorders**
 - breast cancer, 84:129
 - familial adenomatous polyposis (FAP), 84:153
 - kidney cancer, 84:123, 129
 - papillary renal cell carcinoma, 84:123
- Fibroblastoma**
 - giant cell, 80:20
 - t(17;22) in, 80:20
- Fibrosarcoma**
 - fine needle aspiration, 84:27
 - karyotype, 84:27
- Fibrothecoma**
 - chromosome changes in, 83:84
 - ovarian, 83:84
- FISH studies**
 - analysis of paraffin sections, 84:145
 - application to complex changes in CML, 82:93
 - bcl 1, 2 and 3, 85:118
 - centromere association, 85:143
 - correlation with cellular DNA, 84:145
 - detection of + 8 and + 9 in polycythemia, 79:153
 - FISH studies in multiple myeloma, 83:115
 - hsr and dmin by "microfish", 84:143
 - in ALL, 83:46
 - in ALL and NHL, 79:8
 - in ALL with 14q + , 81:83
 - in AML, 83:1
 - in ANLL, 85:1
 - in bladder cancer, 82:163, 170
 - in cervical cancer cell lines, 82:1
 - in cervical dysplasia, 84:146
 - in childhood ALL and NHL, 79:8
 - in choriocarcinomas, 80:9
 - in CLL, 85:118
 - in CML, 81:20; 81:115; 82:93
 - in colorectal cancer, 81:103
 - in endometrial cancer, 80:110, 81:109
 - in ependymomas, 79:173
 - in glioblastoma, 81:118
 - in hamartoma, 84:82
 - in hematologic disorders, 84:148
 - in lung cancer, 84:132
 - in lung cancer cell lines, 80:47
 - in MDS, 82:116; 83:105
 - in meningioma, 85:101
 - in myxoid chondrosarcoma, 84:146
 - in neuroectodermal tumors, 83:12
 - in prostate cancer, 84:132, 85:143
 - in salivary gland adenoma, 79:1
 - in seminoma with i(12p), 81:17
 - in solid tumors and hematological malignancies, 84:134
 - in synovial sarcoma, 84:76
 - in testicular tumors, 85:26
 - interspecies and mixed cell sample studies, 84:153
 - micro-FISH in MDS, 83:105
 - "microfish" studies in sarcomas, 84:143
 - multicolor FISH, 84:145
 - of adrenal tumor cells, 79:36
 - of derivative chromosome 3 in keratinocyte cell line, 84:146
 - of eight-way variant t(15;17) in APL, 83:136
 - of ERBB-3 oncogene, 80:100
 - of i(18q), 81:13
 - of neutrophils and lymphocytes in CML, 83:61
 - of ovarian cancer, 84:145
 - of tetrasomy 8, 79:182
 - of t(1;16), 79:15
 - of t(2;13) in rhabdomyosarcoma, 84:132
 - of t(8;21)(q22;q22) in AML, 79:97
 - of YAC with 3p13-24 sequences, 81:1
 - of 9p - in acute leukemias, 83:46
 - of 20q - in MDS and MPD, 80:87
 - rehybridization of metaphases, 85:58
 - studies of PML-RAR α in leukemia without t(15;17) 80:95
 - studies of single cell trisomy, 85:37
 - + 3 and + 7 in multiple myeloma, 83:115
- Flow cytometry**
 - of pancreatoblastoma, 79:115
- Fluids**

- ascitic, 84:116
FISH studies, 84:116
malignant vs nonmalignant, 84:116
pleural, 84:116
- Fragile sites**
constitutional breakpoints and, 85:78
enhanced expression, 82:123
exposure to pesticides, 82:123
in lymphocytes, 84:51
in Wilms tumor families, 84:51
SCE in, 85:72
- Ganglioglioma**
chromosomes in, 85:155
karyotype, 85:155
- Gastric cancer**
chromosome changes, 81:139, 169
double minutes in, 82:140
MYC and MET amplification, 82:140
progression and MYC and MET, 82:140
3q - as primary change, 81:139
- Gene(s)**
ALL-1 gene rearrangement in MPD, 83:65
amplification, 80:55
bcl 1, 2, and 3 in CLL, 85:118
BCL-6 in lymphoma, 84:139
constitutional mutations of p53 and brain tumors, 82:106
HER-2/neu in breast cancer, 84:129
MIC2 in neuroendocrine tumor, 82:30
MYC and MET in gastric cancer, 82:140
NF-2, 84:24
N-ras in ANLL, 84:60
PRAD1 in polymorphocytic leukemia, 84:69
p53 in CML in blast crisis, 82:35; 84:105
p53 in small cell carcinoma of bladder, 79:111
p53 mutations in ovarian tumor, 85:43
SIL/TAL1 in T-cell ALL and lymphoma, 85:159
suppressor gene in glioma, 84:46
- Gene therapy**
in cancer, 84:131
in situ delivery, 84:131
- Genotypes**
HLA-DQ and -DR in nasopharyngeal carcinoma, 81:42
in nasopharyngeal carcinoma, 81:42
- Germ cell tumors**
chromosome changes, 79:25; 82:62
chromosome 12 in, 82:62
clonal nature, 79:25
hematologic conditions in, 79:25
i(12p) in, 79:25
leukemias in mediastinal tumors, 79:25
mediastinal tumors, 79:25
ovarian, malignant, 82:62
- Giant cell tumor of bone**
fine needle aspiration, 84:27
karyotype, 84:27
- Glioblastoma**
cell line, 81:118
chromosomal changes, 85:61
chromosome 7, 84:73
heterogeneity, polyploidy, aneusomy and 9p - in glioblastoma, multiforme, 83:127
molecular studies, 82:106
multiforme, 81:118
parenchymal vs endothelial cells, 84:73
t(7;10)(p21;q22) in, 81:118
1p - in, 83:160
- Glioma**
autosomal changes, 84:1
chromosomal changes, 85:61
chromosome 1 and glioma growth, 84:46
chromosome 7, 84:73
chromosomes 7 and 10, 84:1
- correlation of grade, morphology and cytogenetics, 85:61
cytogenetic evidence for suppressor gene, 84:46
cytogenetics 84:1, 9, 46
malignant, 84:1, 9
progression, 85:61
sex chromosome changes, 84:1, 9
tumor suppressor gene in glioma, 84:46
t(7;10) in glioblastoma cell line, 84:141
- Hamartoma**
breast, 84:82, 146
chromosome changes, 84:146
FISH studies, 84:82, 146
MAR region in, 84:82, 146
12q changes, 84:82
- Hematologic disorders**
FISH studies, 85:37
PCR studies after BMT, 85:124
single cell trisomy, 85:37
- Hepatoblastoma**
cytogenetics, 84:160
t(1;4) in, 84:160
- Hodgkin disease (HD)**
chromosome changes in, 80:129
phorbol in cytogenetic preparations, 80:129
- Homogeneously staining region (hsr)**
in AML, 82:9
in esophageal cancer, 82:175
in gastric cancer, 81:139
in lung cancer, 81:46
reintegration of C-MYC into hsr in lung cancer cell line, 84:143
- Hypereosinophilia**
features, 80:68
- 7 in, 80:68
- Interphase cytogenetics; also see FISH**
in adrenal tumor cells, 79:36
of t(8;21)(q22;q22), 79:97
two color fluorescence, 79:97
- Inversions**
in breast cancer, 80:33
inv(10)(q11q24) in ATL, 81:175
inv(14q) in B-ALL, 80:72
- Isochromosomes**
in uveal melanoma, 80:40
isochromosomes in renal cell carcinoma, 82:128
i(1q) in neurofibrosarcoma, 81:135
i(3q) in Waldenström macroglobulinemia, 81:92
i(4p) and favorable prognosis in M4, 79:127
i(12p) in mediastinal germ cell tumors, 79:25
i(12p) in seminoma, 81:17
i(12p) in testicular tumors, 85:26, 85:133
i(14q) in T-ALL, 80:78
i(17q) in Wilms tumor, 79:92
i(18q) in immortalized T-cells, 81:13
i(18q) in MDS with myelofibrosis, 79:149
mechanism for i(17q) formation, 80:170
- Karyotypic changes**
in ALL, 80:129
in ANLL, 79:130
in brain tumors, 81:125
in breast cancer, 80:33
in childhood ALL and NHL, 79:8
in choriocarcinomas, 80:9
in chordoma, 85:51
in desmoid tumors, 79:139
in endometrial cancer, 80:110
in ependymomas, 79:173
in gastric and esophageal cancer, 81:139, 169
in germ cell tumors, 79:25
in glioma, 84:1, 9; 85:61

- in immunoblastic lymphoma, 79:59
- in intermediate lymphoma, 79:89
- in leiomyomas, 80:103
- in liposarcoma, 79:104
- in lung cancer cell lines, 84:39
- in lymphomas, 80:129, 81:56
- in MDS, 82:17
- in meningioma, 79:146; 85:91
- in MFH, 79:119; 85:101, 113
- in multiple myeloma, 82:41; 83:71
- in renal cell carcinoma, 82:126
- in renal oncocytomas, 79:164
- in retinoblastoma, 82:155
- in sarcoma, 84:27
- in salivary adenoma, 79:1
- in squamous cell cancer of lung, 81:46
- in stomach cancer, 81:169
- in thyroid tumors, 80:138
- in uveal melanoma, 80:40
- Keratinocyte**
 - cell line, 85:105
 - cytogenetics of cell line, 85:105
 - malignant progression, 85:105
 - molecular studies, 85:105
- Kidney**
 - cancer cell lines, 82:128
 - carcinoid in horseshoe kidney, 84:95
 - chromosome changes in non-neoplastic tissue, 85:152
 - chromosome changes in papillary cancer, 84:123
 - chromosome changes in tumors, 82:126, 84:123
 - chromosome 1 changes in RCC, 82:128
 - chromosomes in oncocytomas, 79:164
 - chromosomes 3 and 7 in RCC, 82:128
 - clear/granular RCC, 82:128
 - cytogenetics in metastasis, 80:168
 - cytogenetics of renal cell carcinoma, 82:126; 84:123
 - double minutes in cancer, 80:169
 - familial, 84:129
 - familial papillary cancer, 84:123
 - isochromosomes in RCC, 82:128
 - mesoblastic nephroma, 84:113
 - metastatic RCC, 80:168
 - molecular studies in papillary cancer, 84:123
 - nephroma (congenital), 84:113
 - oncocyte-like areas in RCC, 84:158
 - oncocytomas, 79:164
 - papillary RCC, 82:128, 84:123
 - pathogenesis of RCC, 84:154
 - renal cell carcinoma, 82:126, 84:123
 - sex chromosome changes in RCC, 82:128
 - subtype with t(X;1), 81:72
 - t(X;1) in RCC, 81:72
 - t(X;1) in RCC of female patient, 84:159
 - t(X;17)(p11.2;q25) in pediatric RCC, 83:82
 - t(5;11)(q35;q13) in oncocytoma, 79:164
 - t(6;11)(p21;q13) in RCC, 84:158
 - 22 in malignant peripheral nerve sheath tumor of kidney, 84:159
- Kostmann disease; see Congenital agranulocytosis**
- Large bowel tumors; see Colorectal cancer**
- Leiomyomas**
 - cytogenetic changes, 80:103
 - epithelioid, 80:103
 - mapping of 12q13-15 breakpoint, 84:140
 - mapping of 12q23-24 breakpoint, 84:139
 - t(6;10)(p21;q22) in, 79:136
 - uterine, 79:136; 80:103; 84:139
 - 7q - in, 81:99
 - 7q - in adenomyosis, 80:118
 - 7q - involving both homologues, 81:99
- Leiomyosarcoma**
 - chromosome changes in hamster tumors, 79:54
 - fine needle aspiration, 84:27
 - karyotype, 84:27
 - spontaneous in Chinese hamster, 79:54
- Lipoma**
 - atypical, 83:32
 - mapping of 12q13-15 breakpoint, 84:140
 - 12q13-14 amplicon in, 83:32
 - 16q loss in spindle cell and pleomorphic lipoma, 84:140
- Lipomatosis; see Multiple lipomatosis**
- Liposarcoma**
 - chromosome 16 and large markers, 84:156
 - fine needle aspiration, 84:27
 - karyotype, 84:27
 - mixed type, 79:104
 - sequencing of t(12;16), 84:140
 - t(12;16)(q13;p11) in, 79:104, 84:140
 - 6q - in, 79:104
 - 12q13-15 amplicon, 83:32
- Liver**
 - childhood hyperplasia, 85:138
 - chromosome changes in hyperplasia, 85:138
 - hyperplasia, 85:138
- Loss of heterozygosity (LOH)**
 - at 1p in brain tumors, 83:160
 - in brain tumors, 83:160
 - 17p LOH in cervical cancer, 79:74
- Lung**
 - cancer, 84:39
 - cancer cell lines, 80:47
 - cell lines, 84:39
 - chromosome changes, 84:39
 - chromosome changes in cell lines, 80:47
 - chromosome changes in inflammatory pseudotumor, 84:158
 - cytogenetic studies in squamous cancer, 81:46
 - evolution during course of disease, 80:47
 - FISH studies, 80:47; 84:132
 - FISH studies in SCLC, 84:132
 - FISH studies of deletions in cancer, 84:148
 - lymphoma, primary, 82:54
 - small cell carcinomas, 80:47
 - squamous cell carcinoma, 81:46
 - tumor suppressor gene on 3p in SCLC, 84:153
 - t(11;12;18)(q13;q13;q12) in lymphoma, 82:54
 - t(11;19) in mucoepidermoid tumor, 80:85
 - 3p - in cancer, 84:148
 - 11p allelotyping, 84:39
- Lymphocytes**
 - chromosome changes, SCE and growth kinetics in Sézary syndrome, 83:75
 - spontaneous SCE, 83:75
- Lymphoma**
 - SIL/TAL1 recombination in ALL and lymphoma, 85:159
- Lymphoma; see Non-Hodgkin lymphoma**
- Lymphomatoid papulosis**
 - cytogenetic findings, 80:13
 - regressing skin lesions, 80:13
- Malignant fibrous histiocytoma (MFH)**
 - chromosome changes in, 79:119
 - cytogenetics, 85:91
 - double minutes (dmin), 85:91
 - MDM2 amplification, 84:143
 - near-haploidy in, 79:119
 - pediatric 84:143
 - 12q13-15 amplicon in, 83:32
- Malignant glioma; see Glioblastoma**
- Malignant histiocytosis**
 - in germ cell tumors, 79:25
- Medulloblastoma**
 - chromosome changes, 81:125
- Melanoma**
 - chromosome changes, 80:40, 82:85; 83:93
 - chromosome 6 and cell growth, 84:153

- clustering of breakpoints, 83:93
- cytogenetics of, 80:40, 82:85, 83:93
- disseminated, 83:93
- karyotype of opossum melanoma, 83:155
- loss of chromosome 10 in metastatic lesions, 84:154
- near-diploid and simple karyotypes, 83:93
- numerical changes, 83:93
- of iris, 82:85
- regional, 83:93
- UV-induced in opossum, 83:155
- uveal, 80:40
- Meningioma**
 - chromosome changes, 79:144, 81:125, 83:160
 - clinical data and PET, 79:144
 - cytogenetics, 85:101, 113
 - FISH studies, 85:101
 - loss of chromosome 14, 85:101
 - loss of chromosome 22, 85:101
 - malignant progression, 85:101
 - molecular studies, 82:106, 83:160
 - monosomy 1p, 79:144, 83:160
 - recurrent, 85:113
 - ROS1 expression, 83:148
 - 1p - in, 83:160
 - 1p - and enhanced glucose metabolism, 79:144
 - 22, 81:125
- Merkel cell carcinoma (MCC); see Neuroendocrine tumors**
- Mesoblastic nephroma**
 - congenital, 84:113
 - cytogenetic changes, 84:113
- Methodologies**
 - cytogenetic preparations, 80:129
 - direct vs culture in prostate cancer, 84:131
 - PCR after BMT, 85:124
 - phorbol in lymphoid malignancies, 80:129
 - rehybridization of metaphases for FISH, 85:58
- Microsatellite repeats**
 - in brain tumors, 84:56
 - in pediatric brain tumors, 84:56
- Molecular studies**
 - after BMT in leukemia, 85:124
 - cloning of 3q21 breakpoint, 80:1
 - in ALL, 84:19, 32
 - in AML, 82:9, 84:60
 - in ANLL, 84:60
 - in APL, 84:91
 - in cervical cancer, 79:74
 - in CLL (bcl 1, 2 and 3), 85:118
 - in CML, 83:35, 93; 84:105
 - in CML with t(11;14), 81:24
 - in colorectal cancer, 81:103, 84:24
 - in Ewing tumor, 83:5
 - in gastric cancer, 82:140
 - in HeLa cells, 85:97
 - in nasopharyngeal carcinoma, 81:42
 - in neuroblastoma cell line, 82:151
 - in neuroectodermal tumors, 83:12
 - in NHL, 79:70
 - in ovarian tumors, 85:43
 - in pancreatic cancer, 84:130
 - in patients with constitutional p53 mutations, 82:106
 - in PML/RAR α in APL, 84:91
 - in prostate cancer, 84:131
 - in salivary gland adenoma, 79:1
 - in T-ALL, 84:32
 - in T-cell diseases, 85:152
 - in testicular tumors, 85:26
 - in trophoblastic neoplasms, 85:5
 - mapping at the single molecular level, 84:150
 - of benign mesenchymal tumors, 84:133
 - of brain tumors, 82:106
 - of constitutional t(1;10)(p22;q21) in patient with neuroblastoma, 81:151
 - of i(18q) in immortalized T-cells, 81:13
 - of microsatellite repeats in brain tumors, 84:56
 - of MPD with ALL-1 rearrangement, 83:65
 - of NotI in 3p21-22, 81:144
 - of PML-RAR α in Ph + leukemia lacking t(15;17), 80:95
 - of p53, 85:43
 - of ROS1 in meningioma, 83:148
 - of tumor suppressor gene at 3p21-22, 81:144
 - of variant Ph chromosomes, 82:93
 - of t(11;14) in multiple myeloma, 83:25
 - of 3q21 breakpoint in hematologic disorders, 80:1
 - of 12q13-15 amplicon in soft tissue tumors, 83:32
 - of 14q + in ALL, 81:83
 - PCR in T-ALL, 81:76
 - PCR in trophoblastic tumors, 85:5
 - rus in pediatric osteosarcoma, 79:49
 - satellite DNA in rat cells, 79:64
 - studies in T-ALL, 81:76
 - YAC with 3p13-24 sequences, 81:1
- Monosomy**
 - 7 in hypereosinophilia, 80:68
 - 22 in brain tumors, 81:125
- Mouse**
 - chromosome 14 in different metastatic tumors, 83:172
- Multiple endocrine neoplasia type I**
 - cytogenetic evaluation, 79:123
 - DEB test in, 79:123
 - double minutes in lymphocytes, 82:50
- Multiple lipomatosis**
 - and childhood cancer, 80:17
 - new association with cancer, 80:17
- Multiple myeloma**
 - Burkitt-type translocation, 82:100
 - cytogenetic findings, 82:41, 82:100, 83:71
 - der(1;15)(q10;q10) in, 83:144
 - FISH studies, 83:115
 - molecular study of t(11;14), 83:25
 - t(8;22)(q24;q11), 82:100
 - t(11;14)(q13;q32) in, 83:25
 - + 3 and + 7, 83:115
- Myelodysplastic syndromes (MDS)**
 - chromosome changes, 82:17, 116
 - chromosome findings and survival, 81:158
 - chromosome painting, 82:17
 - constitutional + 8 mosaicism, 79:79
 - double minutes in, 79:169
 - FISH studies, 82:116, 83:105, 85:37
 - in child with constitutional + 8, 79:79
 - in germ cell tumor, 79:25
 - interstitial der(12)(q15q22) in, 80:158
 - i(18q) and myelofibrosis, 79:149
 - micro-FISH studies, 83:105
 - single cell trisomy, 85:37
 - survival, 81:158
 - X-chromosome translocation, 82:17
 - 5q - syndrome in child, 80:121
 - + 8 and heterogeneity of lineage, 82:116
 - + 13 in MDS, 81:185
 - 20q - in, 80:87
- Myelofibrosis**
 - i(18q) in, 79:149
 - with myelodysplastic syndrome, 79:149
 - 20q - in, 80:87
- Myeloproliferative disorders (MPD)**
 - FISH studies of 20q - , 80:87
 - 20q - in, 80:87
 - molecular studies of MPD with t(9;11), 83:65
 - progression to AML, 83:65
 - t(9;11)(p22;q23) with ALL-1 gene rearrangement, 83:65
- Myxoma**
 - cardiac, 82:161
 - 12p12 in, 82:161

- Nasopharyngeal carcinoma**
 genotypes in, 81:42
 HLA-DQ and -DR genotypes, 81:42
 in China, 81:42
- Natural killer (NK) cells**
 in CML, 79:21
- Near haploidy**
 in MFH, 79:119
- Neuroblastoma**
 amplification units, 82:151
 cell line (NGP), 82:151
 cerebral, 81:125
 chromosome changes, 81:125
 chromosome 12 derived amplifications, 82:151
 deletion at 1p36.2-3, 84:132
 molecular and cytogenetic studies, 84:149
 molecular characterization of t(1;10), 81:151
 t(1;10)(p22;q21), constitutional change, 81:151
 unusual case in adult, 84:157
 1p - in, 83:160
 -22 in adult case, 84:157
- Neuroectodermal tumors**
 chromosome changes, 83:12
 chromosome 17 in CNS tumors, 84:133
 CNS tumors, 84:133
 FISH studies, 83:12
 molecular studies, 83:12; 84:133
 without t(11;22)(q24;q12), 83:12
- Neuroendocrine tumors**
 cutaneous, 82:30
 cytogenetics, 82:30
 differential from other tumors, 82:30
 Merkel cell carcinoma, 82:30
 MIC2 gene, 82:30
 t(3;22) in tumor, 82:30
- Neurofibrosarcoma**
 GAP-related domain, 81:173
 karyotypic evolution, 81:135
 NF-1 gene in, 81:173
 pediatric, 81:135
- Nodular fasciitis**
 cytogenetic changes, 81:166
 of breast, 81:166
- Non-Hodgkin lymphoma (NHL)**
 B-cell small lymphocytic lymphoma and +15, 81:28
 BCL-6 in B-cell lymphoma, 84:139
 CD2 +, CD3 - and CD56 + lymphoma, 82:73
 childhood type, 79:8
 chromosome changes in, 80:129, 81:56, 179; 83:121
 chromosome 8, 79:8
 clonal evolution, 79:59
 correlation of cytogenetics with histology and immunology, 81:56
 cytogenetic changes in leukemic phase, 83:18
 cytogenetics, 80:124, 81:179
 der(6)t(1;16)(q11;p11) in, 79:59
 DNA content, 80:124
 ETS-1 oncogene in, 79:70
 FISH studies, 79:8
 flow cytometry of DNA content, 80:124
 immunoblastic, 79:59, 81:179
 in Japan, 81:56
 intermediate with t(14;19)(q32.3;q13.1) and t(3;22)(q27;q11.2), 79:89
 i(6p) and 6q - in immunoblastic NHL, 81:179
 leukemic phase, 83:18
 lung, primary, 82:54
 lymphoma of lung, 82:54
 molecular, immunologic and cytogenetic approaches, 84:149
 phorbol in cytogenetic preparations, 80:129
 prolymphocytes in lymphoma with +15, 81:28
 recurring abnormalities in, 83:18
 telomere changes, 83:121
 translocations in intermediate type, 79:89
 t(5;9)(q31;q34) in pleomorphic lymphoma, 82:73
 t(11;12;18)(q13;q13;q12) in lung lymphoma, 82:54
 X-chromosome numerical changes, 82:23
 +15 in small lymphocytic lymphoma, 81:28
- Nucleolar Organizer Regions (NOR)**
 Ag-NOR staining, 85:129
 ectopic, 85:129
 in cancer, 85:129
- Oligodendroglioma**
 85:61
- Ollier disease**
 1p - in cartilage lesion, 84:152
 enchondroma, 84:152
- Oncocytomas; see Kidney**
- Oncogene**
 ETS-1 in NHL, 79:70
 localization of ERBB-3, 80:100
 methodologies for gene localization, 80:100
 mutational activation, 79:49
 N-ras in ANLL, 84:60
 PRAD1 in prolymphocytic leukemia, 84:69
 ras in pediatric osteosarcoma, 79:49
 ROS1 in meningioma, 83:148
 TIM at 7q33-35, 83:87
- Osteosarcoma**
 absent ras activation, 79:49
 pediatric, 79:49
 secondary AML in treated patient, 82:103
- Ovary**
 borderline tumor, 85:43
 centromere anomalies in cancer, 80:63
 changes of chromosome 19 in cancer, 84:154
 chromosome changes in fibrothecoma, 83:84
 cytogenetic changes in carcinoma, 79:160
 fibrothecoma, 83:84
 FISH study of chromosome number and oncogenes, 84:154
 germ cell tumors, 82:62
 molecular studies, 85:43
 mucinous cystadenocarcinoma, 79:160
 pseudomyxoma peritonei, 79:160
 p53 in tumors, 85:43
 1p36 changes and t(1;17) in cancer, 84:155
- Pancreas**
 cytogenetics of cancer, 84:135
 cytogenetics of pancreatoblastoma, 79:115
 der(17) in papillary tumor, 84:160
 flow cytometry, 79:115
 molecular studies in cancer, 84:130
 pancreatoblastoma, 79:115; 84:157
- Parotid gland**
 squamous cell carcinoma, 79:157
- PCR**
 in T-cell diseases, 85:152
 of SIL/TAL1, 85:152
- Philadelphia chromosome (Ph)**
 FISH studies of variant Ph's, 82:93
 in ALL with 20q -, 79:32
 Ph + ALL with 14q +, 81:83
 serendipity of, 79:95
 variant in ALL, 80:162
 variant Ph translocation, 80:155, 82:93
 t(2;9;14;22), 80:155
 t(5;9;22)(q35;q34;q11) in ALL, 80:162
- Phyllodes tumor**
 breast, 83:111, 174
 i(1)(q10) in, 83:174
 1q in, 83:111, 174
- Pituitary**
 adenoma, 84:89

- chromosome changes in adenoma, 84:89
lymphocyte cultures, 84:89
- Pleural fluid**
FISH studies, 84:116
malignant vs nonmalignant, 84:116
- Polycythemia vera (PV)**
chromosome changes in, 79:153
FISH studies in, 79:153
secondary polycythemia, 79:153
+ 8 and + 9 in, 79:153
20q - in, 80:87
- Polymerase chain reaction (PCR)**
chromosome changes, 83:121
detection of fusion mRNA in T-ALL, 81:76
in APL, 84:91
p53 studies in ovarian tumors, 85:43
RT/PCR detection of SIL-TAL-1, 81:76
RT-PCR of PML/RAR α , 84:91
studies after BMT, 85:124
studies in trophoblastic disease, 85:5
telomere changes, 83:121
- Polypoid coli**
double minutes in lymphocytes, 82:50
familial, 82:50
- Primed in situ labeling (PRINS)**
methodology, 79:15
of t(1;16), 79:15
- PRINS (Primed in situ labeling)**
in ALL, 84:19
- Programmed cell death**
BCL-2 gene, 84:138
- Prolymphocytic leukemia**
molecular studies in, 84:69
PRAD1 oncogene in, 84:69
t(11;14)(q13;q32) in, 84:69
- Prostate**
cancer, 85:143
centromere association, 85:143
CGH studies, 84:131
chromosomes 9 and 17, 85:143
culture vs direct studies, 84:131
ectopic NOR, 85:129
FISH studies, 84:132
genetic bases of cancer, 84:131
molecular studies in, 84:131
studies (cytogenetic and molecular) in cell lines, 84:141
- Rat cells**
molecular studies, 79:64
satellite I DNA in transformed cells, 79:64
thyroid tumors, 80:138
- Refractory Anemia (RA)**
FISH studies, 80:87
t(X;14)(p11;q32) in, 80:135
20q - in, 80:87
- Refractory Anemia with excess of blasts (RAEB)**
double minutes in, 79:169
interstitial del(12)(q15q22) in, 80:158
20q - in, 80:87
- Refractory Anemia with excess of blasts in transformation (RAEB-t)**
double minutes in, 79:169
+ 8 and cell heterogeneity, 82:116
20q - in, 80:87
- Refractory Anemia with ringed sideroblasts (RARS)**
FISH studies, 80:87
20q - in, 80:87
- Renal tumors; see Kidney**
- Retinoblastoma**
chromosome evolution, 82:155
cytogenetics, 82:115
early rearrangements, 82:155
late rearrangements, 82:155
- Rhabdoid tumor**
cerebral (malignant), 81:125; 84:147
of brain, 84:147
- 22, 81:125; 84:147
- Rhabdomyosarcoma**
alveolar (solid), 80:107; 84:147
alveolar with variant (2;13), 84:147
FISH of interphase, 84:147
FISH study of t(2;13), 84:132
metastatic, 84:147
PAX3/FKHR fusion product, 84:147
t(2;13) in, 80:107
- Ring chromosomes**
in MFH, 79:119
in NHL, 83:121
in uveal melanoma, 80:40
polychromosomal, 85:157
translocation basis, 85:157
- Sarcoma(s)**
cytogenetics of, 84:27
fibrosarcoma, 84:27
fine needle aspiration, 84:27
giant cell tumor of bone, 84:27
leiomyosarcoma, 84:27
liposarcoma, 84:27
synovial sarcoma, 84:27
- Salivary gland**
adenoma, 79:1
breakpoint studies, 79:1
chromosome changes in mucoepidermoid carcinoma, 80:165
chromosome 12 in adenoma, 79:1
FISH studies in adenoma, 79:1
mapping of 12q13-15 breakpoint, 84:140
molecular studies in adenoma, 79:1
mucoepidermoid carcinoma, 80:165
translocations in adenoma, 79:1
t(1;12)(p22;q15) in adenoma, 79:1
t(11;19)(q21;p13.1) in carcinoma, 80:165
YAC studies in adenoma, 79:1
- Sarcoma**
chondrosarcoma, 81:33
cytogenetic analysis of sarcoma of unknown primary site, 84:158
deletion of p16 or amplification of CDK4 and cyclin D, 84:144
endometrial stromal sarcoma, 84:85
GAP-related domain, 81:173
molecular studies, 84:144
neurofibrosarcoma, 81:135, 173
NF-1 gene in, 81:173
t(4;19)(q35;q13.1) in malignant sarcoma, 84:158
- Satellite DNA**
in transformed rat cells, 79:64
satellite I DNA, 79:64
- Secondary leukemia**
AML following therapy for osteosarcoma, 82:103
following chemotherapy, 82:103
in treated osteosarcoma patient, 82:103
t(8;16)(p11;q13), 82:103
- Seminoma; see Testicular tumors**
- Sézary syndrome**
chromosome changes in lymphocytes, 83:75
SCE in lymphocytes, 83:75
- Sister chromatid exchange (SCE)**
chemical induction, 85:72
fragile sites and, 85:72
in acute leukemia, 79:86
in lymphocytes of Sézary syndrome, 83:75
- Sixth International Workshop on Chromosomes of Solid Tumors Skin**
changes in patients with skin tumors, 85:88
cytogenetic studies, 85:16, 88
ectopic NOR, 85:129

- neoplastic cells, 85:16
 sun exposure and cytogenetic changes, 85:16
- Solid tumors**
 aneuploidy in interphase, 84:144
 FISH studies in, 84:134
 rapid FISH protocol, 84:144
 recurrent chromosome changes, 84:134
- Sperm**
 chromosome changes after chemotherapy, 80:29
 FISH studies, 80:29
- Squamous cell carcinoma**
 chromosomes in head and neck cancer, 84:139
 clonal evolution, 79:157
 cytogenetic and molecular studies in oral cancer, 84:139
 cytogenetics of, 81:46; 84:139
 lung, 81:46
 parotid gland, 79:157
 tetraploidization in parotid, 79:157
 6q - in parotid, 79:157
- Stomach cancer; see Gastric cancer**
- 5q - syndrome**
 in child, 80:121
- Synovial sarcoma**
 chromosome 18, 84:76
 fine needle aspiration, 84:27
 FISH studies, 84:76
 karyotype, 84:27
 secondary chromosome changes, 84:156
 t(X;18) in, 84:76, 156
- T-cell(s)**
 adult T-cell leukemia, 81:175
 ALL, 79:177
 cell lines, 85:68
 chromosome changes, 85:68
 cytokine-dependent cultures, 85:68
 inv(10)(q11q24) in ATL, 81:175
 i(18q) in immortalized cells, 81:13
 lymphocytes, 85:68
 SIL/TAL1 recombination in ALL and lymphoma, 85:159
 T-ALL, 84:32
 translocations in T-ALL, 84:148
 t(1;14)(p34;q11) and +8 in T-ALL, 79:177
 t(11;14)(p15;q11) in T-ALL, 84:32
- Techniques; see Methodologies**
- Telomerase**
 in chordoma, 85:51
- Telomere**
 association in MFH, 85:91
 association in various disorders, 83:121
 changes in CLL, 83:121
 changes in CML, 83:121
 changes in hematologic disorders, 83:121
 changes in NHL, 83:121
 changes in PV, 83:121
 in chordoma, 85:51
 telomerase and telomere stability, 84:130
 telomerase inhibitors, 84:130
- Telomeric association**
 cytogenetic progression in pediatric tumors, 84:152
 in hematologic disorders, 83:121
- Teratoma**
 immature, 81:125
 - 22, 81:125
- Testicular tumors**
 carcinoma-in-situ, 85:133
 chromosome changes in sex cord tumors, 84:156
 cytogenetics, 85:26, 85:133
 cytogenetics study of seminoma, 81:17
 ectopic NOR, 85:133
 FISH studies in tumors, 85:26
 germ-cell tumors, 85:133
 high chromosome number, 84:90
 i(12p) in, 85:26
 i(12p) in seminoma, 81:17
 LOH and cytogenetics, 85:26
 molecular studies, 85:26
 precursor for germ cell tumors, 85:133
 reticulum cell sarcoma, 84:157
 seminoma, 81:17
 sex cord stromal tumors, 84:156
- Tetrasomy**
 FISH studies in, 79:182
 tetrasomy 8 in ANLL, 79:182
- Therapy-related acute leukemia; see Secondary leukemia**
- T-lymphocytes; see T-cells**
- Thyroid tumors**
 cell lines, 80:138
 CGH studies in cancer, 84:134
 cryopreservation, 85:20
 cytogenetic, 85:20
 cytogenetics of medullary tumors, 80:138
 goiter, 82:67
 line with t(1;10;21) and ret/H4 chimeric transcript, 84:141
 medullary carcinoma, 80:138
 rat tumors, 80:138
 t(5;19)(q13;q13) in goiter, 82:67
- Translocations**
 basis for polychromosomal rings, 85:157
 in childhood ALL and NHL, 79:8
 jumping translocations in ALL, 80:80
 translocations in neuroendocrine tumors, 82:30
 t(X;1)(p11.2;p13) in lung cancer cell lines, 84:39
 t(X;1)(p11.2;q21) in RCC, 81:72; 84:159
 t(X;1)(p22;p11) in MDS, 82:17
 t(X;1)(q27;q25) in MDS, 82:116
 t(X;1;3;15;17;18) in synovial sarcoma, 84:27
 t(X;3)(q13;p12) in MDS, 82:17
 t(X;6)(p22;q22) in multiple myeloma, 82:41
 t(X;6)(q23;q24) in melanoma, 83:93
 t(X;7)(q21.2;q11.2) in dermatofibrosarcoma protuberans, 80:75
 t(X;8)(q21-22;q13) in squamous lung cancer, 81:46
 t(X;9)(q28;q12) in glioblastoma, 81:125
 t(X;11)(p11;q21) in testicular tumor, 85:26
 t(X;11)(q13;q24) in MDS, 82:17
 t(X;12)(q13;q24.3) in MDS, 82:17
 t(X;12;14)(q22;p12;q21) in MDS, 82:17
 t(X;14)(p11;q32) in refractory anemia, 80:135
 t(X;15)(q10;q10) in multiple myeloma, 82:41
 t(X;17)(p11.2;q25) in pediatric RCC, 83:82
 t(X;17)(p21;q12) in MDS, 82:17
 t(X;17)(p21;q22) in MDS, 82:17
 t(X;18)(p11;q11) in synovial sarcoma, 84:27
 t(X;19)(q22;p11) in MDS, 82:17
 t(X;20)(q13;q12) in MDS, 82:17
 t(X;21)(p11;q21) in MDS, 82:17
 t(1;1)(p22;q11) in testicular tumor, 85:26
 t(1;2)(p11;q11) in lymphoma, 80:129
 t(1;2;8)(p22;p12;q24) in multiple myeloma, 82:41
 t(1;2)(p36;p23) in multiple myeloma, 82:41
 t(1;2)(p36;q13) in glioma, 85:61
 t(1;2)(q12;q21.2) in glioma, 85:61
 t(1;2)(q10;q13) in melanoma, 83:93
 t(1;2)(q21;p23) in inflammatory pseudotumor of lung, 84:158
 t(1;2)(q21;q24) in squamous lung cancer, 81:46
 t(1;2)(q25;q37) in renal cell carcinoma, 82:128
 t(1;2)(q23;q31) in multiple myeloma, 82:41
 t(1;2)(q32;p13) in NHL, 81:56
 t(1;2)(q32;q37) in multiple myeloma, 83:71
 t(1;3)(p32;p21) in multiple myeloma, 82:41
 t(1;3)(p34;q21) in lymphoplasmacytic lymphoma, 83:18
 t(1;3)(q12;p24) in leiomyosarcoma, 84:27
 t(1;3)(q21;p12) in glioma, 85:61
 t(1;3)(q12;q29) in melanoma, 83:93

- t(1;3)(q21;q12) in giant cell tumor of bone, 84:27
 t(1;3)(q22;q25) in immunoblastic lymphoma, 81:179
 t(1;3)(q25;p21;q34) in multiple myeloma, 82:41
 t(1;3)(q32;q22) in melanoma, 83:93
 t(1;3)(q42;p12) in leiomyoma, 79:136
 t(1;4)(p11;q11) in meningioma, 79:147
 t(1;4)(p11;q12) in NHL, 81:56
 t(1;4)(p22;q35) in NHL, 81:56
 t(1;4)(p34;q13) in renal cell carcinoma, 82:128
 t(1;4)(p36.3;q31.1 or 3) in breast cancer, 80:33
 t(1;4)(q21;q32) in lymphoma, 83:18
 t(1;4)(q25;p10) in lung cancer cell lines, 84:39
 t(1;5)(q21;q12) in ganglioglioma, 85:155
 t(1;6;16)(p11;q21;p13.3) in multiple myeloma, 82:41
 t(1;6)(p13;p11) in NHL, 81:56
 t(1;6)(p31;p11) in melanoma, 83:93
 t(1;6;7;6;17;15;12;3)(p22;q27;p15;q13;q21;q22;q13;p13),
 XX:XX
 t(1;6)(q11;p11) in lymphoma, 79:59
 t(1;6)(q11;q11) in melanoma, 83:93
 t(1;6)(q11;q16) in multiple myeloma, 82:41
 t(1;6)(q21;q21) in multiple myeloma, 82:41
 t(1;6)(q21;q23) in glioma, 84:1
 t(1;6)(q31;q21) in melanoma, 83:93
 t(1;7)(p11;p21) in melanoma, 83:93
 t(1;7)(p13;p13) in endometrial cancer, 80:110
 t(1;7)(p22;p11) in multiple myeloma, 82:41
 t(1;7)(q11;q36) in melanoma, 83:93
 t(1;7)(q12;p22) in glioma, 84:1
 t(1;7)(q12;q36) in lung cancer cell line, 80:47
 t(1;7)(q42;q10) in multiple myeloma, 82:41
 t(1;7)(q42;q35) in lymphoma, 80:129
 t(1;8)(p13;q11) in squamous lung cancer, 81:46
 t(1;8)(p34;q24) in melanoma, 83:93
 t(1;8)(q25;p11) in duodenal cancer, 82:146
 t(1;9)(p11;p11;p11) in cervical cancer, 82:1
 t(1;9)(p11;p11) in renal cell carcinoma, 82:128
 t(1;9)(p13;p11) in lung cancer cell lines, 84:39
 t(1;9)(p36.3;p24) in cervical cancer, 82:1
 t(1;9;22)(p36;q34;q11) variant Ph in CML, 82:93
 t(1;9)(q11;p13) in melanoma, 83:93
 t(1;9)(q12;p22) in alveolar soft part sarcoma, 82:57
 t(1;9)(q21;p22) in ALL, 80:162
 t(1;9)(q21;p23) in melanoma, 83:93
 t(1;10)(p11;q11) in renal cell carcinoma, 82:128
 t(1;10)(p22;q11.2) in melanoma, 83:93
 t(1;10)(p22;q21) constitutional in patient with neuroblas-
 toma, 81:151
 t(1;10)(p22;q22) in MFH, 85:91
 t(1;11)(q12;p11) in multiple myeloma, 82:41
 t(1;11)(q21;p15) in endometrial cancer, 80:110
 t(1;11)(q23;q23) in melanoma, 83:93
 t(1;11)(q24;q13) in duodenal cancer, 82:146
 t(1;12)(p13;q12) in leiomyoma, 83:93
 t(1;12)(p22;q15) in salivary gland adenoma, 79:1
 t(1;12)(p31;p12) in cardiac myxoma, 82:161
 t(1;12)(p31;q32) in breast cancer, 80:33
 t(1;12)(p36;q13) in glioma, 84:1
 t(1;12)(p36;q13) in NHL, 81:56
 t(1;12)(p36;q24) in multiple myeloma, 82:41
 t(1;12)(q10;q24.3) in retinoblastoma, 82:155
 t(1;12)(q21;p13) in squamous lung cancer, 81:46
 t(1;12)(q31;q13) in glioma, 84:1
 t(1;12)(q42;q13) in glioma, 84:1
 t(1;13;17)(p22;q11;p11) in multiple myeloma, 82:41
 t(1;13)(q10;q10) in multiple myeloma, 82:41
 t(1;13)(q21;q34) in ALL, 79:8
 t(1;14)(p10;q10) in multiple myeloma, 82:41
 t(1;14)(p34;q11) in T-ALL, 79:177
 t(1;14)(q13;q32) in chordoma, 84:152
 t(1;14)(q21;q32) in lymphoma, 83:18
 t(1;15)(p36;q26) in multiple myeloma, 82:41
 t(1;15)(q10;q10) in multiple myeloma, 82:41
 t(1;15)(q11;q15) in multiple myeloma, 82:41
 t(1;15)(q11;q26) in multiple myeloma, 82:41
 t(1;15)(q21;p11.2) in pancreatoblastoma, 84:157
 t(1;15)(q21;p12) in lymphoma, 83:18
 t(1;15)(q31;q21) in lung cancer cell lines, 84:39
 t(1;16)(q11 or q12;p11.1 or q11.1) in ANLL, 79:15
 t(1;16)(q25;q13) in melanoma, 83:93
 t(1;16)(q32;q22) in paraganglioma, 84:157
 t(1;16)(q42;q13) in glioma, 84:46
 t(1;17)(p13;p11) in squamous lung cancer, 81:46
 t(1;17)(21;q21) in renal cell carcinoma, 82:128
 t(1;18)(p36.3;q21) in cervical cancer, 82:1
 t(1;18)(q11;p13.3) in multiple myeloma, 82:41
 t(1;19)(p11;q13.4) in multiple myeloma, 82:41
 t(1;19)(p13;q13.3) in multiple myeloma, 82:41
 t(1;19)(q12;q13) in melanoma, 83:93
 t(1;19)(q21;p13) in renal cell carcinoma, 82:128
 t(1;19)(q21;q13) in glioma, 85:61
 t(1;19)(q23;p13) in follicular lymphoma, 83:18
 t(1;19)(q42;q13 or p13) in glioma, 84:46
 t(1;20)(q12;p13) in duodenal cancer, 82:146
 t(1;20)(q25;p10) in liver hyperplasia, 85:138
 t(1;21)(p11;q11.2) in NHL, 81:56
 t(1;21)(p13;p13) in cervical cancer, 82:1
 t(1;21)(q10;q10) in multiple myeloma, 82:41
 t(1;21)(q11;q21) in multiple myeloma, 82:41
 t(1;21)(q21;p11.2) in glioblastoma, 81:125
 t(1;22)(q10;q10) in endometrial cancer, 80:110
 t(1;22)(q11;p11) in pre-B ALL, 82:88
 t(1;22)(q12;p11.2) in reticulum cell sarcoma, 84:157
 t(2;2)(p23;q21) in glioma, 85:61
 t(2;3)(p11;q27) in NHL, 81:56
 t(2;3)(p21;p13) in T-CLL, 81:186
 t(2;3)(p22;q28) in myeloid disorders, 79:130
 t(2;3)(q37;q21) in squamous lung cancer, 81:46
 t(2;4)(q23;q23) in multiple myeloma, 82:41
 t(2;5)(p23;q35) in lymphoma, 80:129
 t(2;5)(q21;q12) in lung cancer cell lines, 84:39
 t(2;6)(q21;q27) in melanoma, 83:93
 t(2;7)(p13;p22) in blast phase of CML, 81:182
 t(2;7)(p21;q22) in NHL, 81:56
 t(2;7)(p22;q11.2) in melanoma, 83:93
 t(2;7)(p23;p13) in NHL, 81:56
 t(2;7)(p21;p22) in NHL, 81:56
 t(2;7)(q22;p21) in melanoma, 83:93
 t(2;7)(q37;q11) in multiple myeloma, 82:41
 t(2;8)(p12;q24) in multiple myeloma, 82:41
 t(2;9;14;22)(p21;q34;q32;q11) in Ph translocation, 80:155
 t(2;9)(q31;q13) in cervical cancer, 82:1
 t(2;9)(q37;q11) in NHL, 81:56
 t(2;10)(p22;q10) in melanoma, 83:93
 t(2;10)(q14-21;p11.2) in leiomyosarcoma, 84:27
 t(2;11)(p25;q13) in squamous lung cancer, 81:46
 t(2;11)(q21;p14) in lung cancer cell lines, 84:39
 t(2;11)(q32;q13) in lung cancer cell lines, 84:39
 t(2;11)(q35;p13) in MDS, 83:105
 t(2;12)(p13;q13) in ANLL, 80:23
 t(2;13)(q35;q14) in rhabdomyosarcoma, 84:147
 t(2;13)(q36;q14) in rhabdomyosarcoma, 80:107
 t(2;14)(p13;q32) in ALL, 83:140
 t(2;15)(q31;q26) in nodular fasciitis, 81:166
 t(2;15)(q34;q26) in glioma, 84:1
 t(2;15)(q37;q15) in medulloblastoma, 81:125
 t(2;15)(q37;q21) in renal cell carcinoma, 82:128
 t(2;18)(q21;q21) in lymphoma, 83:18
 t(2;19)(q21;q13) in renal cell carcinoma, 82:128
 t(2;22)(q13;q13) in glioma, 85:61
 t(3;3)(p25;q21) in lymphoma, 83:18
 t(3;3)(q12;p11) in NHL, 81:56
 t(3;3)(q21;q26) in ANLL, 80:1
 t(3;4)(p10;p10) in lung cancer cell lines, 84:39
 t(3;4)(p13;p16) in breast cancer, 80:33
 t(3;4)(p13;q35) in renal cell carcinoma, 82:128

- t(3;4)(q21.1;q25) in NHL 81:56
 t(3;4)(q27;q25) in NHL 81:56
 t(3;5)(p11;p11) in lung cancer cell lines, 84:39
 t(3;5)(p21;q33) in renal cell carcinoma, 82:128
 t(3;5)(q11;q11.2) in NHL, 81:56
 t(3;5)(q22-23;q32) in gastric cancer, 81:169
 t(3;6)(p11;p11.2) in lung cancer cell lines, 84:39
 t(3;6)(p13;q21) in glioma, 85:61
 t(3;6)(p13;q25) in multiple myeloma, 82:41
 t(3;6)(p21;q12) in medulloblastoma, 81:125
 t(3;6)(q12;p12) in lung cancer cell lines, 84:39
 t(3;6)(q21;q27) in endometrial stromal sarcoma, 84:85
 t(3;6)(q29;p21.1) in endometrial stromal sarcoma, 84:85
 t(3;7)(p12;q21) in meningioma, 79:147
 t(3;7)(p21;q11) in renal cell carcinoma, 82:128
 t(3;7)(p21;q36) in renal cell carcinoma, 82:128
 t(3;8)(p14;q13) in renal cell carcinoma, 82:128
 t(3;8)(p22;q12) in melanoma, 83:93
 t(3;8)(p25.1;q13.3) in AML, 82:9
 t(3;8)(q21;p21;p22) in lymphoma, 83:18
 t(3;9)(p14p25;p22) in duodenal cancer, 82:146
 t(3;9)(p22;q24;q11) variant Ph in CML, 82:93
 t(3;9)(q11;q12) in melanoma, 83:93
 t(3;9)(q21;p11q34) in renal cell carcinoma, 82:128
 t(3;9)(q21;p24) in melanoma, 83:93
 t(3;9)(q21;q34) in endometrial cancer, 80:110
 t(3;10)(q12;p11.2) in lung cancer cell lines, 84:39
 t(3;10)(q21;p13) in duodenal cancer, 82:146
 t(3;11)(p12;q22) in MDS, 82:17
 t(3;11)(q10;p10) in lung cancer cell line, 80:47
 t(3;11)(q11;p13) in NHL, 81:56
 t(3;11)(q12;p15.1) in bladder cancer, 82:170
 t(3;11)(q21;q13) in AML, 83:119
 t(3;12)(q21;p11.2) in melanoma, 83:93
 t(3;12)(q27;q24) in melanoma, 83:93
 t(3;13)(p11;p11) in melanoma, 83:93
 t(3;13)(q21;q32) in lymphoma, 83:18
 t(3;14)(p11;q11) in thyroid tumor, 80:138
 t(3;14)(p21;q23-24) in breast cancer, 80:33
 t(3;14)(q10;p10) in lung cancer cell line, 80:47
 t(3;14)(q27;q11) in NHL, 81:56
 t(3;15)(p14;q26) in melanoma, 83:93
 t(3;15)(q11;p11) in renal cell carcinoma, 82:128
 t(3;17)(p12;q11) in glioma, 85:61
 t(3;17)(p11;p11) in multiple myeloma, 82:41
 t(3;17)(q21;q22 or q23) in breast cancer, 80:33
 t(3;20)(q11;q11.2) in NHL, 81:56
 t(3;22)(q27;q11) in NHL, 81:56
 t(3;22)(q27;q11.2) in intermediate lymphoma, 79:89
 t(4;5)(q13;q12) in lymphoma, 80:129
 t(4;5)(q21;p15) in lymphoma, 83:18
 t(4;7;11;5)(p12;p11;q13;q13) in renal cell carcinoma, 82:128
 t(4;7)(q21.1;p21) in melanoma, 83:93
 t(4;7)(q31;p22) in duodenal cancer, 82:146
 t(4;9)(p16;p13) in lung cancer cell lines, 84:39
 t(4;9)(p16;q22) in lung cancer cell lines, 84:39
 t(4;9)(q35;q12) in cardiac myxoma, 82:161
 t(4;10)(q11;p15) in squamous lung cancer, 81:46
 t(4;11)(q25;p15) in squamous lung cancer, 81:46
 t(4;12)(p16;q13) in blast phase of CML, 81:182
 t(4;12)(q10;q10) in glioblastoma, 81:125
 t(4;12)(q21;p13) in breast cancer, 80:33
 t(4;13)(p12;q12) in melanoma, 83:93
 t(4;14)(p14;q32) in lymphoma, 83:18
 t(4;15)(p13;q13) in glioma, 85:61
 t(4;17)(p13;q12) in MDS, 82:17
 t(4;17)(q21;q25) in glioma, 85:61
 t(4;18)(q26;p11.3) in breast cancer, 80:33
 t(4;19)(q35;q13.1) in malignant sarcoma, 84:158
 t(4;21)(q13;p11) in lymphoma, 80:129
 t(4;21)(q34;q11) in gastric cancer, 81:169
 t(5;6)(p15;p11) in melanoma, 83:93
 t(5;6)(q13;q21) in medulloblastoma, 81:125
 t(5;6)(q23;q25) in glioma, 84:1
 t(5;6)(q31;q21) in congenital leukemia (M5), 81:38
 t(5;6)(q35;p21.3) in chondrosarcoma, 84:146
 t(5;7)(q13;p22) in gastric cancer, 81:139
 t(5;8)(q31;q22) in glioma, 84:1
 t(5;9)(q31;q34) in lymphoma, 82:73
 t(5;9;22)(q35;q34;q11) Ph in ALL, 80:162
 t(5;10)(q12;p13) in multiple myeloma, 82:41
 t(5;11)(p11;q22) in glioma, 84:1
 t(5;11)(p15;q22) in glioma, 84:1
 t(5;11)(q35;q13) in oncocyoma (renal), 79:164
 t(5;12)(q13;p13) in chordoma, 85:51
 t(5;12)(q31;p11.2) in angiosarcoma, 84:146
 t(5;14)(p10;q10) in multiple myeloma, 82:41
 t(5;14)(p15;q13) in NHL, 81:56
 t(5;15)(p11;p13) in multiple myeloma, 82:41
 t(5;15)(p15;q13-15) in ALL, 83:90
 t(5;17)(q13;q25) in endometrial cancer, 80:110
 t(5;18)(q13;q21) in CML, 85:89
 t(5;19)(q13;q13) in thyroid goiter, 82:67
 t(5;21)(q13;q22) in blast phase of CML, 81:182
 t(5;22)(q11.2;q11.2) in multiple myeloma, 82:41
 t(6;6)(q13;p24) in blast phase of CML, 81:182
 t(6;7)(p11;p11) in renal cell carcinoma, 82:128
 t(6;7)(q12;q11) in lymphoma, 80:129
 t(6;7)(q25;p13) in NHL, 81:56
 t(6;7)(q25;q22) in chordoma, 85:51
 t(6;7)(q27;q31) in breast cancer, 80:33
 t(6;8)(q15;p22) in multiple myeloma, 82:41
 t(6;8)(q27;q21.3) in astrocytoma, 81:125
 t(6;9)(q13;q13) in melanoma, 83:93
 t(6;10)(p21.3;p11.2) in chondrosarcoma, 84:146
 t(6;10)(p21;q22) in leiomyoma, 79:136
 t(6;10)(q11;q11.2) in lung cancer cell lines, 84:39
 t(6;10)(q23;q24) in NHL, 81:56
 t(6;10)(q24;p14) in lung cancer cell line, 80:47
 t(6;11)(p11;q21) in testicular tumor, 85:26
 t(6;11)(p21;p13) in melanoma, 83:93
 t(6;11)(p21;q13) in RCC, 84:158
 t(6;11)(q27;q23) in M5, 82:76
 t(6;12)(p12;p11.2) in lung cancer cell lines, 84:39
 t(6;13)(p10;q10) in uveal melanoma, 80:40
 t(6;13)(q11;q11) in lymphoma, 80:129
 t(6;14)(p21;q32) in lymphoma, 83:18
 t(6;14)(q11;q11) in NHL, 81:56
 t(6;15)(q13;q12) in melanoma, 83:93
 t(6;16)(p11;p11) in glioma, 84:1
 t(6;17)(q11;q11) in retinoblastoma, 82:155
 t(6;17)(q21;p11.2) in glioblastoma, 81:125
 t(6;18)(q15;q21) in NHL, 81:56
 t(6;19)(p21;p13) in duodenal cancer, 82:146
 t(6;19)(q11.1;q21) in breast cancer, 80:33
 t(6;20)(q16;q13) in melanoma, 83:93
 t(6;22)(q13;p13) in multiple myeloma, 82:41
 t(6;22)(q11;p13) in melanoma, 83:93
 t(7;7)(p21;q11) in squamous lung cancer, 81:46
 t(7;7)(p22;q36) in melanoma, 83:93
 t(7;7)(q21;p21) in melanoma, 83:93
 t(7;7)(q35;q21) in papillary renal cancer, 84:123
 t(7;8)(p11;q11) in renal cell carcinoma, 82:128
 t(7;8)(q11;p23) in glioma, 85:61
 t(7;8)(q36;q22) in renal cell carcinoma, 82:128
 t(7;9)(p21;q12) in ependymoma, 79:173
 t(7;9)(q11;q22) in renal cell carcinoma, 82:128
 t(7;9)(q11.2;q12) in melanoma, 83:93
 t(7;9)(q21;p22) in multiple myeloma, 82:41
 t(7;9)(q34;q34) in T-ALL, 83:46
 t(7;10)(p21;q22) in glioblastoma, 81:118
 t(7;10)(p21;q22) in glioblastoma cell line, 84:141
 t(7;10)(q22;q22) in glioma, 85:61
 t(7;10)(q22;q22.3) in melanoma, 83:93
 t(7;11)(p11;p15) in renal cell carcinoma, 82:128
 t(7;11)(q11;p11) in squamous lung cancer, 81:46

- t(7;12)(p22;q13) in glioma, 84:1
 t(7;12)(q11;q11) in hamartoma, 84:146
 t(7;12)(q22-31;q13-14) in angiomyxoma, 84:156
 t(7;12;14)(q22q32;q24;q24) in T-CLL, 81:186
 t(7;13)(p13;q34) in glioma, 84:1
 t(7;14)(p11;q11) in glioma, 84:1
 t(7;14)(q10;q10) in thyroid tumor, 80:138
 t(7;14)(q32;q24) in T-CLL, 81:186
 t(7;15)(p22;q12) in multiple myeloma, 82:41
 t(7;15)(q22;q15) in NHL, 81:56
 t(7;15)(q34;q21) in blast phase of CML, 81:182
 t(7;16)(p14;q13.1) in melanoma, 83:93
 t(7;16)(q31;p13.3) in breast cancer, 80:33
 t(7;17)(p21;p11) in cardiac myxoma, 82:161
 t(7;19)(q22;q11) in duodenal cancer, 82:146
 t(7;20)(q11.2;q13.3) in glioma, 85:61
 t(7;20)(q31;p13) in breast cancer, 80:33
 t(7;22)(p11;p11) in melanoma, 83:93
 t(8;9;22)(q24;q34;q11) variant Ph in CML, 82:93
 t(8;10)(p22;p12) in melanoma, 83:93
 t(8;10)(q10;q10) in glioblastoma, 81:125
 t(8;11)(p21;q13) in T-CLL, 81:186
 t(8;11)(q21;p15) in squamous lung cancer, 81:46
 t(8;11)(q24;q13) in lymphoma, 83:18
 t(8;13)(qter;q22) in breast cancer, 80:33
 t(8;13)(q13;q12) in MFH, 79:119
 t(8;14) in childhood ALL and NHL, 79:8
 t(8;14)(q10;p10) in multiple myeloma, 82:41
 t(8;14)(q11;p12) in melanoma, 83:93
 t(8;14)(q21;q32) in multiple myeloma, 82:41
 t(8;14)(q22;q32) in multiple myeloma, 82:41
 t(8;14)(q24;q32) in multiple myeloma, 82:41
 t(8;15)(q10;q10) in multiple myeloma, 82:41
 t(8;16)(p11;p13) in secondary leukemia, 82:103
 t(8;17)(p11.2;q12) in melanoma, 83:93
 t(8;17)(qter;q23) in breast cancer, 80:33
 t(8;17)(q11;q21) in leiomyoma, 80:103
 t(8;17)(q13;q25) in blast phase of CML, 81:182
 t(8;17)(q24;q23) in ependymoma, 79:173
 t(8;20)(q22;p11.2) in NHL, 81:56
 t(8;21)(q22;q22) in AML, 79:97
 t(8;21)(q22;q22) in de novo MSA, 79:82
 t(8;22)(q24;q11) in multiple myeloma, 82:100
 t(8;22)(q24;q12) in lymphoma, 80:129
 t(9;9)(p13;q22) in blast phase of CML, 83:46
 t(9;9)(p24;q13) in squamous lung cancer, 81:46
 t(9;10;15;17;22)(q34;p13;q23;q21;q11) variant Ph in CML, 82:93
 t(9;11)(p13;p11) in testicular tumor, 85:133
 t(9;11)(p21;p15.5) in thyroid tumor, 80:138
 t(9;11)(q11;p11) in renal cell carcinoma, 82:128
 t(9;11)(q12;p11.2) in lung cancer cell lines, 84:39
 t(9;11)(q32;q12) in endometrial cancer, 80:110
 t(9;13)(p11;q11) in melanoma, 83:93
 t(9;14)(p21;q32.3) in glioblastoma, 81:125
 t(9;15)(p11;q11) in melanoma, 83:93
 t(9;15)(p11;q11) in renal cell carcinoma, 82:128
 t(9;15;22)(q34;q26;q11) variant Ph in CML, 82:93
 t(9;17)(p13;p11) in blast phase of CML, 81:182
 t(9;17)(p24;q21) in renal cell carcinoma, 82:128
 t(9;17)(q11;p11) in squamous lung cancer, 81:46
 t(9;17)(q11;q11) in immunoblastic lymphoma, 81:179
 t(9;17;22)(q22;q23;q11) variant Ph in CML, 82:93
 t(9;17)(q22.3;p11.2) in NHL, 81:56
 t(9;17)(q34;q21) in astrocytoma, 81:125
 t(9;22)(q12;p12) in gastric cancer, 81:139
 t(9;22)(q13;q13) in breast cancer, 80:33
 t(9;22)(q22;q12) in chondrosarcoma, 81:33
 t(9;22)(q34;q11) in ALL, 80:129, 83:121
 t(9;22)(q34;q11) in CML, 83:121
 t(10;11)(p13;q13) in NHL, 81:56
 t(10;11)(q22.3;q13) in melanoma, 83:93
 t(10;12)(p15;p12) in multiple myeloma, 82:41
 t(10;12)(q22;q15) in leiomyoma, 80:103
 t(10;12)(q24;q13) in NHL, 81:56
 t(10;13)(q26;q13) in breast cancer, 80:33
 t(10;15)(q24;p11) in multiple myeloma, 82:41
 t(10;15)(q24;q21) in cervical cancer, 82:1
 t(10;17)(q11;p11) in melanoma, 83:93
 t(10;17)(q11;p13) in renal cell carcinoma, 82:128
 t(10;21)(p11;q11) in squamous lung cancer, 81:46
 t(11;12;18)(q13;q13;q12) in lung lymphoma, 82:54
 t(11;13)(p15;q12) in NHL, 81:56
 t(11;14)(p11;q11) in NHL, 81:56
 t(11;14)(p13;q11) in M7, 83:42
 t(11;14)(p13;q11) in T-ALL, 84:32
 t(11;14)(q11;q32) in multiple myeloma, 82:41
 t(11;14)(q13;q32) in B-CLL, 83:121
 t(11;14)(q13;q32) in mantle cell lymphoma, 83:18
 t(11;14)(q13;q32) in multiple myeloma, 82:41; 83:25, 71
 t(11;14)(q13;q32) in NHL, 81:56
 t(11;14)(q13;q32) in Ph + CML, 81:24
 t(11;14)(q13;q32) in polyclonal lymphoma, 84:69
 t(11;14)(q14;q31) in multiple myeloma, 82:41
 t(11;14)(q23;q32) in NHL, 81:56
 t(11;15)(p10;q10) in breast cancer, 80:33
 t(11;16)(q23;q24) in M5, 82:76
 t(11;18)(q11;p11.2) in melanoma, 83:93
 t(11;19)(q11;q13.3) in multiple myeloma, 82:41
 t(11;19)(q14;q11) in lymphoma, 80:129
 t(11;19)(q21;p11) in mucocystic tumor of lung, 80:85
 t(11;20)(q13;q11) in duodenal cancer, 82:146
 t(11;22)(p15;q13) in multiple myeloma, 82:41
 t(11;22)(q23;q12) in paraganglioma, 84:157
 t(11;22)(q24;q12) in Ewing tumor, 84:147
 t(12;13)(p13;q21) in renal cell carcinoma, 82:128
 t(12;13)(q24.1;q34) in immunoblastic lymphoma, 81:179
 t(12;14)(q13;q32) in lymphoplasmacytic lymphoma, 83:18
 t(12;15)(p12;q25) in mesoblastic nephroma, 84:113
 t(12;16)(q10;p10) in medulloblastoma, 81:125
 t(12;16)(q13;p11) in liposarcoma, 79:104
 t(12;16)(q13;p11) in myxoid liposarcoma, 84:27
 t(12;16)(q15;q24) in melanoma, 83:93
 t(12;17)(q13;q21) in ANLL, 80:23
 t(12;17)(q13;q21) in glioma, 84:46
 t(12;19)(p11;p11) in testicular tumor, 85:26
 t(12;19)(q13;q13) in renal cell carcinoma, 82:128
 t(12;20)(q12;q13) in endometrial cancer, 80:110
 t(12;21)(q13;q21) in ANLL, 80:23
 t(12;22)(p11;p13) in endometrial cancer, 80:110
 t(13;13)(q10;q10) in gastric cancer, 81:139
 t(13;13)(q10;q10) in pancreaticoblastoma, 79:115
 t(13;14)(p11;q11) in melanoma, 83:93
 t(13;14)(q10;q10) in gastric cancer, 81:139
 t(13;14)(q10;q10) in multiple myeloma, 82:41
 t(13;14)(q11;p11) in renal cell carcinoma, 82:128
 t(13;14)(q31;q11.2) in carcinoma of kidney, 84:95
 t(13;15)(p12;q11) in melanoma, 83:93
 t(13;17)(q14;p11) in pancreatic papillary tumor, 84:160
 t(13;19)(qter;q22) in breast cancer, 80:33
 t(13;21)(q12;q22) in papillary renal cancer, 84:123
 t(13;22)(p10;q10) in multiple myeloma, 82:41
 t(13;22)(q10;q10) in pancreaticoblastoma, 79:115
 t(14;14)(p11;q11) in melanoma, 83:93
 t(14;14)(p11;q13) in glioma, 85:61
 t(14;14)(q32;q12) in T-CLL, 83:121
 t(14;15)(q10;q10) in melanoma, 83:93
 t(14;15)(q32;q24) in lung cancer cell lines, 84:39
 t(14;17)(p10;q10) in NHL, 83:121
 t(14;17)(q22;q21) in APL, 80:160
 t(14;18)(q10;q10) in thyroid tumor, 80:138
 t(14;18)(q32;q21) in follicular lymphoma, 83:18
 t(14;18)(q32;q21) in lymphoma, 80:129, 81:56
 t(14;18)(q32;q21) in NHL, 83:121
 t(14;19)(p11;p11) in melanoma, 83:93
 t(14;19)(q11.2;p13.1) in glioma, 85:61

- t(14;19)(q22;q13) in meningioma, 79:147
 t(14;19)(q32.3;q13.1) in intermediate lymphoma, 79:89
 t(14;22)(p13;q11) in MFH, 79:119
 t(14;22)(q13;p12) in glioma, 85:61
 t(15;16)(q11;q11) in renal cell carcinoma, 82:128
 t(15;16)(q22.3;q23) in melanoma, 83:93
 t(15;17)(p10;p10) in multiple myeloma, 82:41
 t(15;17)(q22;p13) in NHL, 81:56
 t(15;22)(q15;q11) in NHL, 81:56
 t(16;19)(q13;p13) in gastric cancer, 81:139
 t(16;21)(q21;q22.1) in retinoblastoma, 82:155
 t(17;18)(q11.2;p11.3) in glioma, 85:61
 t(17;18)(q11;q23) in duodenal cancer, 82:146
 t(17;19)(q21;p13) in endometrial cancer, 80:110
 t(17;19)(q21;q13) in melanoma, 83:93
 t(17;19)(q21;q13) in thyroid tumor, 80:138
 t(17;20)(p11.2;p12) in papillary renal cancer, 84:123
 t(17;20)(q21;q13.3) in multiple myeloma, 82:41
 t(17;20)(q21;q13.3) in thyroid tumor, 80:138
 t(17;21)(p12;q21) in bladder cancer, 82:170
 t(17;22)(q21;33;q13.1) in fibroblastoma, 80:20
 t(18;20)(q21;q11) in bladder cancer, 82:170
 t(18;21)(q11.2;q22) in chordoma, 84:152
 t(19;21)(p13;q11) in ALL, 80:162
 t(20;20)(q11.1;q13.3) in glioblastoma, 81:125
- Trisomy**
 chromosome 8 in ANLL, 85:1
 chromosome 15 in adrenal tumor cells, 79:36
 in normal kidney tissues, 85:152
 in tumors, 80:171
 mosaic +8 (constitutional) in child with MDS, 79:79
 mosaic +8 (constitutional) in patient with trophoblastic disease, 80:150
 in tumors, 80:171
 single cell trisomy in hematologic disorder, 85:37
 +3 and +7 in multiple myeloma, 83:115
 +4 and AML, 79:186
 +4 in biphenotypic acute leukemia, 80:66
 +4 with double minutes in AML, 83:165
 +5 in AML, 84:120
 +7 in colon adenoma, 82:82
 +8 and desmoid tumors, 79:139
 +8 and lineage heterogeneity in MDS, 82:116
 +8 and +9 in polycythemia, 79:153
 +8 and +18 in breast cancer, 80:33
 +8 cells (Ph-negative) during CML therapy, 81:20
 +8 in alveolar soft part sarcoma, 81:94
 +8 in T-ALL, 79:177
 +8:significance of acquired anomaly in various states, 83:176
 +12 and EBV in CLL, 82:80
 +12 in lymphoma, 83:18
 +15 in small lymphocytic lymphoma, 81:28
 +18 in Waldenström macroglobulinemia, 81:92
- Tumor suppressor gene**
 molecular studies, 81:144; 84:130
 3p21-22 region and suppressor gene, 81:144, 84:130
- Tumors**
 disomy and trisomy in, 80:171
- Trophoblastic disease**
 constitutional +8 mosaicism, 80:150
 genetic markers, 85:5
 gestational, 80:150
 malignant, 85:5
 PCR polymorphism, 85:5
- Ureter**
 chromosome changes in non-neoplastic, 83:28
 - Y in non-neoplastic, 83:28
- Uterus**
 adenomyosis, 80:118
 cytogenetics of adenomyosis, 80:118
 cytogenetics of endometrial cancer, 80:110
 leiomyomas, 79:136; 80:103
 t(6;10)(9p21;q22) in leiomyoma, 79:136
 7q - in adenomyosis, 80:118
- Uveal melanoma**
 cytogenetics, 80:40
 isochromosomes, 80:40
- von Hippel-Lindau (VHL) disease**
 gene, 84:129
 pheochromocytoma and VHL, 84:129
 renal cell cancer, 84:129
- Waldenström macroglobulinemia**
 i(3q) in, 81:92
 tetrasomy 3q and +18 in, 81:92
- Wilms tumor**
 chromosome 7 in, 79:92, 81:97
 constitutional and acquired chromosome 7 changes, 81:97
 familial, 84:51
 fragile sites, 84:51
 in XYY male, 84:157
 i(7q) in, 79:92
 translocations, 81:97
- X-chromosome**
 changes in RCC, 82:128
 in gliomas, 84:1, 9
 loss of glioma, 85:61
 numerical changes in NHL, 82:23
 painting of X-chromosome, 82:17
 translocations in MDS, 82:17
 t(X;14)(p11;q32) in RA, 80:135
- Xeroderma pigmentosum**
 dicentric chromosome, 79:41
 fibroblast clone, 79:41
 5p and 16q in fibroblast clone, 79:41
- Y-chromosome**
 changes in RCC, 82:128
 in gliomas, 84:1, 9
 loss of glioma, 85:61
 XYY male with ALL, 83:176
 - Y in bladder cancer, 82:163
 - Y in neo-neoplastic ureter, 83:28
 - Y in squamous cell carcinomas of lung, 81:46
- YAC studies**
 in ALL with 9p -, 83:46
 in ALL with 14q +, 81:83
 in salivary gland adenoma, 79:1
 YAC containing 3p13-21 sequences, 81:1

